

Antimicrobial Stewardship



Federal Bureau of Prisons Clinical Guidance

November 2022



Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates all cases are evaluated on an individual basis and treatment decisions are individual-specific. Referenced Program Statement versions within this guideline are for informational purposes only. Please refer to the most current versions of any referenced Program Statement(s). Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp

ABOUT THIS DOCUMENT

This document contains an **OVERVIEW AND KEY PRINCIPLES**, followed by 16 separate **TOPICS** related to Antimicrobial Stewardship. This guidance is newly designed so that the topics can be consulted separately or together. The topics are listed as clickable links on the next page. For details on what a particular topic covers, see the short table of **CONTENTS** at the beginning of that chapter.

PRINTING: Most likely, you are viewing this document in PDF format. To print an individual topic without printing the entire document, use the page numbers listed below.

TO PRINT THIS TOPIC IN THE PDF VERSION...	PRINT PAGES...	TO PRINT THIS TOPIC IN THE PDF VERSION...	PRINT PAGES...
1. Overview and Key Principles	4-7	9. <i>Clostridium difficile</i> Infection	38-41
2. Acute Rhinosinusitis	8-12	10. Probiotics	42-43
3. Pharyngitis	13-15	11. Urinary Tract Infections	44-49
4. Acute Bronchitis	16-17	12. Asymptomatic Bacteriuria	50-51
5. Pneumonia	18-21	13. <i>Helicobacter pylori</i>	52-54
6. Otitis Media	22-23	14. Dental Infection	55-60
7. Purulent Skin and Soft Tissue Infections (include MRSA)	24-34	15. Surgical Site Infection Prophylaxis	61
8. Non-Purulent Skin and Soft Tissue Infections	35-37	16. Epididymitis	62-63

WHAT'S NEW IN THIS GUIDANCE?

In the November 2022 revision of the BOP guidance on Antimicrobial Stewardship updates were made throughout the document. Major updates to the guidance include:

- [Acute Rhinosinusitis](#)
 - Due to increasing resistance of *S. pneumonia* and *H. influenza*, treatment with macrolides or trimethoprim/sulfamethoxazole should be avoided.
- [Community Acquired Pneumonia](#)
 - Guidance updated to focus on outpatient management of community-acquired pneumonia.
- [Otitis Media](#)
 - Treatment duration updated for 7-10 days for all patients requiring systemic antibiotics.
- [Non-purulent Skin and Soft Tissue Infections \(SSTIS\)](#)
- [Clostridium difficile Infection](#)
 - Updates to Treatment table
- [Asymptomatic Bacteriuria \(ASB\)](#) section added
- [Dental Infection](#)
 - Clindamycin is no longer recommended for antibiotic prophylaxis for a dental procedure.
- [Epididymitis](#) section added
- [Appendix A. Interpretation of a Culture and Sensitivity \(C&S\) Report](#) added

NOTE these changes have altered the pagination, such that the above printing instructions for most of the topics have changed.

TOPICS

Click on any of the following topics to go to that chapter. Note each chapter starts on its own page 1.

1. [Overview and Key Principles](#)
 2. [Acute Rhinosinusitis](#)
 3. [Pharyngitis](#)
 4. [Acute Bronchitis](#)
 5. [Community Acquired Pneumonia](#)
 6. [Otitis Media](#)
 7. [Purulent Skin and Soft Tissue Infections \(SSTIs\), Including MRSA](#)
 8. [Non-Purulent Skin and Soft Tissue Infections \(SSTIs\)](#)
 9. [Clostridium difficile Infection](#)
 10. [Probiotics](#)
 11. [Urinary Tract Infections](#)
 12. [Asymptomatic Bacteriuria \(ASB\)](#)
 13. [Helicobacter pylori](#)
 14. [Dental Infection](#)
 15. [Surgical Site Infection Prophylaxis](#)
 16. [Epididymitis](#)
- [Appendix A. Interpretation of a Culture and Sensitivity \(C&S\) Report](#)

1. OVERVIEW AND KEY PRINCIPLES

CONTENTS

A. Goals of the BOP Antimicrobial Stewardship Program.....	1
B. CDC Core Elements of Antimicrobial Stewardship	2
C. Key Components of Antimicrobial Stewardship	2
D. Interventions to Improve Antimicrobial Prescribing	3
Streamlining.....	3
IV to PO Conversion	3
General Interventions.....	4
E. Development of a Local Antimicrobial Stewardship Team	4
F. Educational Resources	4
G. References	4

Antimicrobial resistance is a significant problem throughout the world—leading to increased morbidity, mortality, and healthcare costs. The Centers for Disease Control and Prevention (CDC) states antibiotic resistance is one of the world’s most pressing public health problems. The CDC estimates at least 2.8 million illnesses and 35,000 deaths in the U.S. are caused by resistant bacteria each year.

The growth of resistant microbes is largely due to inappropriate antimicrobial prescribing practices. Studies have shown antibiotic use is unnecessary or inappropriate in as many as 50% of the cases in the United States. Common prescribing concerns include unnecessary antimicrobials, overuse of broad-spectrum antibiotics, ineffective agents, wrong doses, and extended durations of therapy.

To combat these circumstances, the BOP Antimicrobial Stewardship Program has been developed. This program relies upon a common centralized approach that is augmented by local institution efforts.

A. Goals of the BOP Antimicrobial Stewardship Program

1. Improve patient outcomes.
2. Decrease antimicrobial resistance.
3. Decrease unnecessary antibiotic use.
4. Decrease antimicrobial adverse events.

B. CDC Core Elements of Antimicrobial Stewardship

- Leadership commitment
- Accountability
- Drug expertise
- Action
- Tracking
- Reporting
- Education

C. Key Components of Antimicrobial Stewardship

- 1. EDUCATION:** Recommended topics should address the appropriate use of antibiotics (e.g., antibiotics used for bacterial infections, but not viral infections; many colds do not require antibiotics; risk of overuse, etc.). Topics can include, but are not limited to, current clinical practice guidelines, drug utilization reviews, current diagnostic methods, peer review findings, risks of antibiotic use, and drug information.

Education is recommended for all stakeholders in the healthcare system, including:

- Prescribers
- Staff who administer or distribute medications
- Patients
- Executive Staff
- Department Heads
- Non-medical staff

→ See [Educational Resources](#) below.

- 2. FORMULARY MANAGEMENT:** The BOP utilizes a formulary with varying degrees of restrictions. Medications are either *unrestricted* (no co-sign required) or *restricted* (physician co-sign required). Additionally, some medications may be restricted to use for certain diagnoses. Depending upon local circumstances, the pharmacy and therapeutics (P&T) committees in some institutions may choose to place additional restrictions on BOP National Formulary medications or to remove certain items from their local formularies. Restrictions on a formulary medication may include limited duration of use, use limited to certain diagnoses, removal from the formulary based on local resistance patterns, or *local prior approval* (see below).
- 3. LOCAL PRIOR APPROVAL:** As part of *formulary management*, the local P&T committee may restrict a formulary medication so that approval from the institution's clinical director or pharmacist, or both is required. Local prior approval, when used, is often applied to second-line therapy and may require culture and sensitivity data.

D. Interventions to Improve Antimicrobial Prescribing

- De-escalation: Convert empiric therapy to narrow therapy (see [Streamlining](#) below).
 - Dose optimization: Adjust dosing for renal insufficiency, hepatic insufficiency, body weight, etc.
 - Converting IV to PO (see [IV to PO](#) below).
 - Automatic Stop Orders, with mandatory reassessment in 48–72 hours: Reassess the patient once cultures/sensitivities come back; assess whether the patient is improving on the current regimen.
 - Alerts for duplicate therapy.
 - Distribution of antibiograms, if available.
 - Analysis of antimicrobial resistance rates, if available.
 - Surveillance of antimicrobial usage.
 - Conducting prescribing audits, with feedback to individual prescribers.
- ★ **Note:** *When determining specific dosing of medications, providers should consider if alternate medication selection or dosing adjustment is necessary due to unrelated conditions (i.e., pregnancy, hepatic disease, renal disease, etc.).*

STREAMLINING

Streamlining refers to the practice of converting a patient from broad-spectrum to narrow-spectrum antimicrobial therapy. If a provider starts a patient on empiric treatment with broad-spectrum antimicrobials, narrowing the treatment selection is recommended to better meet the patient's specific needs once culture and sensitivity data are available. This may involve changing antibiotics, reducing the number of medications, or discontinuing treatment.

Benefits associated with streamlining include:

- Reduced secondary infections
- Decreased morbidity and mortality
- Minimized antimicrobial resistance
- Minimized toxicity and adverse effects
- Reduced healthcare expenses

IV TO PO CONVERSION

The IV to PO conversion promotes many positive clinical outcomes, including:

- Increased quality of life
- Decreased risk of the adverse events associated with IV infusions
- Decreased administration errors, due to the ease of PO administration
- Decreased risk of the secondary infections related to IV catheters
- Hastened discharge for patients in inpatient beds
- Decreased costs related to medications
- Decreased laboratory monitoring
- Decreased personnel time for preparation and administration

GENERAL INTERVENTIONS

- Recommend pharmacy, lab, and quality improvement staff prepare and submit annual reports to the P&T committee that include general antibiotic usage data, antibiograms, and review of prescriber usage.
- Recommend quality improvement and health services staff should review, disseminate, and provide training on infection prevention protocols, including hand-washing, catheter, and other protocols meant to reduce the risk of infection.

E. Development of a Local Antimicrobial Stewardship Team

It is recommended each institution develop an *Antimicrobial Stewardship Team*. This is particularly important for all Care Level 3 and Care Level 4 institutions.

Recommended members of the team include:

- Advanced practice practitioner
- Infection prevention and control specialist
- Laboratory personnel
- Nurse
- Pharmacist
- Physician

F. Educational Resources

- *Centers for Disease Control and Prevention (CDC), Antibiotic Prescribing and Use:*
<https://www.cdc.gov/antibiotic-use/index.html>
- *Infectious Diseases Society of America (IDSA):*
<http://www.idsociety.org/Index.aspx>
- *Society of Infectious Diseases Pharmacists (SIDP):*
<http://sidp.org/>
- *The Joint Commission, Antimicrobial Stewardship:*
https://www.jointcommission.org/topics/hai_antimicrobial_stewardship.aspx

G. References

- Centers for Disease Control and Prevention. *Antibiotic/Antimicrobial Resistance (AR/AMR).*
<https://www.cdc.gov/drugresistance/>
- Sanchez, G. V., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. Core Elements of Outpatient Antibiotic Stewardship. *MMWR Recomm Rep.* 2016;65(No. RR-6):1–12. DOI:
<http://dx.doi.org/10.15585/mmwr.rr6506a1>
- Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at:
<https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf>

2. ACUTE RHINOSINUSITIS

CONTENTS

A. Key Points	1
B. Antimicrobial Therapy for ABRS.....	2
C. References	3
D. About the Algorithms	3
E. Algorithm: ARS/ABRS Differential Diagnosis & Treatment Approach.....	4
F. Algorithm: Treating ABRS with Antibiotics.....	5

A. Key Points

- **DEFINITION OF ACUTE RHINOSINUSITIS (ARS):** ARS is defined as up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) **PLUS** nasal obstruction and/or facial pain-pressure-fullness.
★ *Nasal obstruction and/or facial pain-pressure-fullness without purulent discharge is NOT considered ARS.*
- **ETIOLOGY OF ARS:** Causes of ARS include allergens, environmental irritants, viruses, bacteria, and fungi. Most cases of ARS ($\geq 98\%$) are viral. The prevalence of bacterial infection during ARS is estimated to be 0.5–2% and is usually self-limiting.
★ *Consequently, antibiotics are NOT indicated for the majority of ARS cases.*
- **ACUTE BACTERIAL RHINOSINUSITIS (ABRS):**
 - **DIAGNOSIS:**
 1. Signs and symptoms of ARS (as defined above) are persistent and fail to improve after 10 days or more beyond the onset of upper respiratory symptoms.
OR
 2. Signs and symptoms of ARS worsen within 10 days after initial improvement (also known as **DOUBLE WORSENING**).
 - **NATURAL HISTORY AND INITIAL MANAGEMENT:** Most cases of ABRS are self-limiting and resolve without antibiotic therapy. Although antibiotics may shorten the duration of the illness, they are also likely to cause adverse effects. Adults with diagnosed ARBS should be offered watchful waiting and symptomatic management for a 7-day observation period (after the initial 10-day period used to diagnose ARBS).
★ *Antibiotics can be initiated if symptoms fail to improve after 7 days or worsen at ANY time.*
★ *Patients with immunocompromised conditions should be treated on a case-by-case basis.*
 - **URGENT REFERRAL:** Urgent referral is indicated for complicated ABRS or in cases of high persistent fever ($>102^{\circ}\text{F}$), periorbital edema/inflammation, cranial nerve palsies, abnormal extraocular movements, proptosis, vision changes, severe headache, altered mental status, or meningeal signs.

B. Antimicrobial Therapy for ABRS

1. INITIAL ORAL THERAPY (ADULTS):

- Amoxicillin 500mg po tid **OR** 875mg po bid **OR**
- Amoxicillin-Clavulanate 875mg/125 mg po bid **OR**
- Amoxicillin-Clavulanate* ER 2000mg/125mg po bid (high dose for higher risk of pneumococcal resistance or poor outcomes; will require non-formulary approval)
 - * *Clinicians may consider high dose Amoxicillin-Clavulanate over Amoxicillin if bacterial resistance is likely or if presence of moderate-to-severe infection, age \geq 65, immunocompromised patients, antibiotics in the last month, and/or presence of comorbidities (diabetes or chronic cardiac, hepatic, or renal diseases).*

• **EXCEPTION – ADULT PATIENT WITH PENICILLIN TYPE 1 ALLERGY (E.G., ANAPHYLAXIS):**

- Doxycycline 100mg po bid **OR**
- Levofloxacin 750mg po daily **OR** Moxifloxacin 400mg po daily**
 - ** *Reserve fluoroquinolones for patients who have NO alternative treatment options; the serious adverse effects associated with fluoroquinolones generally outweigh the benefits.*

• **EXCEPTION – ADULT PATIENT WITH PENICILLIN TYPE 2 ALLERGY (E.G., SKIN RASH):** Third generation cephalosporin:

- Cefdinir 300mg po bid **OR** 600mg po q24h + Clindamycin 300mg q6h **OR**
- Cefpodoxime 200mg po q12h + Clindamycin 300mg q6h **OR**
- Cefixime 400mg po q24h + Clindamycin 300mg q6h
 - ★ *Due to increasing resistance of *S. pneumonia* and *H. influenza*, treatment with macrolides or trimethoprim/sulfamethoxazole should be avoided.*

2. DURATION: Initial therapy should continue for a total of 5–7 days. If failure occurs after initial therapy and ABRS is re-evaluated and confirmed, a total course of 7–10 days is recommended.

3. FAILURE OF INITIAL ORAL THERAPY:

Patients who have worsening symptoms or fail to improve within 7 days on initial antibiotic therapy should have the diagnosis of ABRS re-evaluated. If ABRS is confirmed, broaden coverage and/or switch to a different drug class, listed below.

- Amoxicillin-Clavulanate ER 2000mg/125mg po bid **OR**
- Doxycycline 100mg po bid for patients who are beta-lactam allergic **OR**
- Third generation cephalosporin plus Clindamycin 300 mg q6h **OR**
- Levofloxacin 750mg po daily **OR** Moxifloxacin 400mg po daily**
 - ** *Reserve fluoroquinolones for patients who have no alternative treatment options; the serious adverse effects associated with fluoroquinolones generally outweigh the benefits.*

4. RELAPSE AFTER ORAL THERAPY:

A recurrence within 2 weeks of successfully completing an antibiotic course is considered a **RELAPSE**.

- MILD SYMPTOMS: Treat with the same antibiotic for longer duration.
- MODERATE TO SEVERE SYMPTOMS: Resistance is likely; consider an alternative drug class.

5. MULTIPLE FAILURES OF ORAL ANTIBIOTICS:

- If the patient fails a second course of appropriate therapy, consider referral to a specialist.

C. References

- Patel, Z. M., Hwang, P. H. (2021) Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. In L. Kunins, S. Bond (Ed.), *UpToDate*. Retrieved March 1, 2022 from <https://www.uptodate.com/contents/uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment>
- Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Kumar, K. A., Kramper, M., Orlandi, R. R., Palmer, J. N., Patel, Z. M., Peters, A., Walsh, S. A., & Corrigan, M. D. (2015) Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*, 152:S1. <https://doi.org/10.1177/0194599815572097>


D. About the Algorithms

The following algorithms for decision-making in treating ARS and ABRS appear on the next two pages:

- ARS/ABRS Differential Diagnosis & Treatment Approach
- Treating ABRS with Antibiotics

Both algorithms are adapted from the sources listed in the *References* section above.


E. Algorithm: ARS/ABRS Differential Diagnosis & Treatment Approach



* See Algorithm for Treating ABRS with Antibiotics on next page.

ADAPTED FROM: Rosenfeld, et al., and Patel & Hwang. See previous [References](#) section.

F. Algorithm: Treating ABRS with Antibiotics



ADAPTED FROM: Rosenfeld, et al., and Patel & Hwang. See previous [References](#) section.

3. PHARYNGITIS

CONTENTS

A. Key Points 1
B. References: 1
C. Algorithm: Treatment of Pharyngitis 2

A. Key Points


- **TREATMENT:**
 - Most adults with acute pharyngitis have a self-limiting illness that should be treated with supportive care only.
 - The benefits of antibiotic treatment of adult pharyngitis are limited to patients with group A streptococcal (GAS) infection. GAS is the etiologic agent in approximately 5–15% of adult cases of pharyngitis.
- **DIAGNOSIS:**
 - Clinical features alone are unreliable in differentiating between GAS and viral pharyngitis, except where overt viral features are present (e.g., rhinorrhea, cough, oral ulcers, and/or hoarseness).
 - Because the signs and symptoms of streptococcal and non-streptococcal (usually viral) pharyngitis overlap, diagnosis should be accomplished through laboratory testing with either a throat culture or a rapid antigen detection test (RADT).
 - Centor criteria can aid in differentiating bacterial from viral pharyngitis. Those patients with a Centor score < 3 have a low probability of GAS pharyngitis and further testing is not warranted. Patients with a Centor score ≥3 have a greater probability of GAS pharyngitis and testing may be indicated.
 - Centor criteria include one point for each of the following: tonsillar exudates, tender anterior cervical lymphadenopathy, fever, and absence of cough
 - Throat cultures are *not* recommended for confirming negative RADT results in adults. Throat cultures may be indicated when investigating outbreaks of GAS infection, as a means of monitoring the development and spread of antibiotic resistance, or when pathogens such as gonococcus are being considered.

B. References:

- Centers for Disease Control and Prevention. (2017). *Antibiotic Prescribing and Use in Doctor’s Offices: Adult Treatment Recommendations*. Retrieved from: <https://www.cdc.gov/antibiotic-use/community/for-hcp/outpatient-hcp/adult-treatment-rec.html>
- Shulman, S.T., Bisno, A. L., Clegg, H. W., Gerber, M. A., Kaplan, E. L., Lee, G., Martin, J. M., & Van Beneden, C. (2012) Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 55(10), e86–e102. <https://doi.org/10.1093/cid/cis629>

- Pichichero, M. (2021). Treatment and prevention of streptococcal pharyngitis in adults and children. In S. Bond, L. Kunins (Ed.), *UpToDate*. Retrieved March 1, 2022, from <https://www.uptodate.com/contents/treatment-and-prevention-of-streptococcal-pharyngitis-in-adults-and-children>

C. Algorithm: Treatment of Pharyngitis



NOTES:

¹ RADT tests should only be performed under structured waived testing programs, and each site must have their own CLIA waiver and ensure that the test being utilized is a CLIA-waived variety. Throat cultures are not recommended for confirming negative RADT results in adults. Throat cultures may be indicated when investigating outbreaks of GAS infection, as a means of monitoring the development and spread of antibiotic resistance, or when pathogens such as gonococcus are being considered.

² Cephalexin or cefadroxil are preferred agents for penicillin-intolerant patients; however, they are to be avoided in individuals with immediate type hypersensitivity to penicillin.

➔ Consider pill line for patients with compliance concerns.

³ All patients with pharyngitis should be offered, or be referred to the commissary for, appropriate doses of analgesics, antipyretics, and other supportive care, in accordance with the BOP National Formulary Part I, Over the Counter Prescribing Criteria Matrix.

Adapted from: Shulman ST, et al. See [References](#).

4. ACUTE BRONCHITIS

CONTENTS

A. Key Points	1
B. Communicating with the Patient: Tips to Reduce Antibiotic Use.....	1
C. References	1
D. Algorithm: Treatment of Acute Bronchitis	2

A. Key Points

- Acute bronchitis, also known as a “chest cold,” occurs when the airways in the lungs swell and produce mucus, causing a person to cough.
- Exposure to secondhand smoke, chemicals, dust, or air pollution can increase the risk for acute bronchitis. A weakened immune system or contact with another person with bronchitis can also increase the risk.
- Most causes (>90%) of acute bronchitis are viral in nature, and include respiratory syncytial virus, adenovirus, influenza, and parainfluenza.
- Treatment should generally be focused on supportive care and patient education
- Signs and symptoms of acute bronchitis include coughing, fatigue, mild headache, mild body aches, fever, watery eyes, and sore throat. Most symptoms last for up to 2 weeks, but coughing can last up to 8 weeks.
★ *The presence of purulent sputum is NOT predictive of bacterial infection.*
- Diagnosis should include ruling out pneumonia. In healthy, non-elderly adult patients, pneumonia is uncommon in the absence of vital sign abnormalities or with findings of consolidation on lung auscultation.


B. Communicating with the Patient: Tips to Reduce Antibiotic Use

- Refer to acute cough illness as a “chest cold” to reduce the patient’s expectation for antibiotics.
- Tell patients antibiotic use increases the risk of an antibiotic-resistant infection.
- Identify and validate the patient’s concerns and recommend specific therapy to address symptoms.
- Spend time answering questions and offer a contingency plan if symptoms worsen.
- REMEMBER: Effective communication is more important than an antibiotic for patient satisfaction.

C. References

- Centers for Disease Control and Prevention. (n.d.). *Chest Cold (Acute Bronchitis)*
<https://www.cdc.gov/antibiotic-use/bronchitis.html>

D. Algorithm: Treatment of Acute Bronchitis



5. COMMUNITY ACQUIRED PNEUMONIA

CONTENTS

A. Key Points	1
B. Culture and Sensitivity (C&S) Notes.....	2
C. Antibiotic Resistance.....	3
D. References	3
E. Algorithm: Treatment of CAP.....	4

A. Key Points

- **COMMUNITY-ACQUIRED PNEUMONIA (CAP):** An incidence of pneumonia demonstrated by select clinical signs and symptoms that occurs in the community or institutional setting.
 - *Common bacterial pathogens in CAP include Streptococcus pneumoniae, Haemophilus influenza, Mycoplasma pneumonia, Staphylococcus aureus, Legionella species, Chlamydia pneumonia, and Moraxella catarrhalis. Pathogens vary based on patient’s comorbidities. Comorbidities that will help to guide treatment include chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia.*
 - *Diagnosis of pneumonia should be confirmed with chest radiograph, however, follow-up chest radiograph after the completion of treatment is not recommended.*
 - ➔ *This guidance focuses on the pathogens, diagnostic criteria, and treatment guidelines for CAP.*
- **DIAGNOSIS:** Pneumonia is diagnosed according to suggestive clinical features (cough, fever, sputum production, pleuritic chest pain, leukocytosis), in addition to a demonstrable infiltrate by chest radiograph (or other imaging technique). When the patient will be treated in the *outpatient setting*, additional diagnostic tests to include sputum cultures/gram stains, blood cultures, and pulse oximetry, are not recommended. In addition, urine antigen testing is not recommended except in cases of severe CAP (see IDSA Guidelines).
 - ★ *Prior to diagnosing pneumonia, providers should consider the possibility of tuberculosis and evaluate accordingly.*

- **DETERMINATION OF INPATIENT VERSUS OUTPATIENT TREATMENT LOCATION:** The Pneumonia Severity Index (PSI) is a clinical prediction tool to be used in conjunction with clinical judgement in determining need for hospitalization.
 - Patients with a PSI ≤ 90 (risk classes I, II, or III) are candidates for outpatient treatment.
 - ★ The CURB -65 is no longer favored or recommended for use to determine the need for hospitalization in adult CAP.

FACTOR	POINTS
Age (male)	Age (years)
Age (female)	Age (years minus 10)
Nursing home resident	10
Neoplastic disease	30
Liver disease	20
Congestive heart failure	10
Cerebrovascular disease	10
Renal disease	10
Altered mental status	20
Respiratory rate ≥ 30 /min	20
Systolic pressure < 90 mm Hg	20
Temperature $< 35^{\circ}\text{C}$ or $\geq 40^{\circ}\text{C}$	15
Pulse ≥ 125 /min	10
Arterial pH < 7.35	30
Blood urea nitrogen ≥ 30 mg/dL	20
Sodium < 130 mmol/L	20
Glucose ≥ 250 mg/dL	10
Hematocrit $< 30\%$	10
PaO ₂ < 60 mm Hg	10
Pleural effusion	10
PSI CLASS	POINTS
I	*
II	≤ 70
III	71 - 90
IV	91 – 130
V	> 130

B. Culture and Sensitivity (C&S) Notes

- Sputum gram stain and culture is *not* routinely recommended for those in the outpatient setting.
- In the hospital setting: Pretreatment sputum gram stain and culture is recommended for those who are being empirically treated for MRSA or *P. aeruginosa*; or were previously infected with MRSA or *P. aeruginosa* (especially those with prior respiratory tract infection); or were hospitalized and received parenteral antibiotics, whether during the hospitalization event or not, in the last 90 days; or those in the hospital setting who are classified as severe CAP (especially if they are intubated).
- Blood cultures are *not* routinely recommended for those in the outpatient setting or the hospital setting. However, blood cultures are recommended for those in the hospital setting which meet the same criteria as described above, or are classified as severe CAP (see IDSA guidelines).
- Serum procalcitonin levels should not be used to determine need for initial antibiotic use. Empiric antibiotics should be initiated if CAP is clinically suspected regardless of serum procalcitonin levels.
- Medical Centers are encouraged to create antibiograms to help guide prescribing.

C. Antibiotic Resistance

Resistance to commonly prescribed antibiotics for CAP is a major consideration in choosing empiric antibiotic treatment. Patient assessment for possible infection by multidrug resistant (MDR) pathogens is recommended to determine if alternate treatment should be considered.


- **Risk factors for MRSA or *Pseudomonas aeruginosa***
 - Prior respiratory isolation of MRSA or *P. aeruginosa*
 - Recent hospitalization AND receipt of parenteral antibiotics (in the past 90 days)

D. References

- Metlay, J., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *American Journal of Respiratory and Critical Care Medicine* 200(7), e46-e67. <https://doi.org/10.1164/rccm.201908-1581ST>
- Chambers, H. F. (2020). Pneumonia, community-acquired, adult, out-patient. *Sanford Guide*. Retrieved March 1, 2022 from <https://webedition.sanfordguide.com/en/sanford-guide-online/disease-clinical-condition/pneumonia-community-acquired>
- Lee, R. A., Centor, R. M., Humphrey, L. L., Jokela, J. A., Andrews, R., Qaseem, A., Akl, E. A., Bledsoe, T. A., Forcica, M. A., Haeme, R., Kansagara, D. L., Marcucci, M., Miller, M. C., & Obley, A. J. (2021) Appropriate use of short-course antibiotics in common infections: Best practice advice from the american college of physicians. *Ann Intern Med.* 174(6), 822-827. <https://doi.org/10.7326/M20-7355>

E. Algorithm: Treatment of Outpatient CAP

- **DIAGNOSIS:** Clinical exam (cough, fever, sputum production, leukocytosis, pleuritic chest pain) and CXR; consider tuberculosis.
- **OTHER SUPPORTING DIAGNOSTIC CRITERIA (if indicated):** O2 sat, cultures (blood, sputum)



6. OTITIS MEDIA

CONTENTS

A. Bacterial Etiologies.....	1
B. Key Points.....	1
C. Diagnosis	1
D. Empiric Antibiotic Therapy	2
E. Antibiotic Therapy for Treatment Failure	2
F. References.....	2

A. Bacterial Etiologies

- Streptococcus pneumoniae (49%)
- Haemophilus influenzae (29%)
- Moraxella catarrhalis (28%)

B. Key Points

- **ACUTE OTITIS MEDIA (AOM)** occurs primarily in childhood. Diagnosis and treatment are therefore largely extrapolated from studies in children.
- Seasonal allergic rhinitis and/or upper respiratory infections are the most important pathological factors in the development of AOM.
- Clindamycin is not active against *H. influenzae* or *M. catarrhalis*, two common bacterial contributors of otitis media.
- Due to the prevalence of drug-resistant *Strep. pneumoniae*, trimethoprim/sulfamethoxazole and macrolides are no longer recommended.
 - Up to 50% of *Strep. Pneumoniae* is resistant to macrolides.
 - *Strep. Pneumoniae* resistant to macrolides is also typically resistant to clindamycin.

C. Diagnosis

- AOM is usually marked by the presence of middle ear fluid and inflammation of the mucosa that lines the middle ear space.
- AOM is often caused by obstruction of the eustachian tube, resulting in fluid retention and suppuration of retained secretions.
- A triad of bulging tympanic membrane, impaired tympanic membrane mobility, and redness and/or opacification of tympanic membrane predicted the diagnosis of AOM in 83–99% of cases. If these three are not present, the provider should consider other possible diagnoses.
- Purulent otorrhea may be present with tympanic membrane rupture.
- AOM is usually unilateral, and hallmark symptoms include otalgia and decreased hearing.
- Other clinical manifestations include conductive hearing loss, fever, pain behind the ear, and facial paralysis.

(list continues on next page)

- Otitis media with effusion (OEM), also known as serous otitis media, usually follows AOM. It is defined by the presence of middle ear fluid without signs of illness or inflammation of the middle ear mucosa.
 - ★ OEM usually resolves spontaneously and does not require antibiotic treatment.

D. Empiric Antibiotic Therapy

- **Amoxicillin remains the drug of choice:**
 - No antibiotics in the prior month: Amoxicillin 1000mg every 8 hours.
 - Antibiotics within the prior month: Amoxicillin-clavulanate 875/125mg BID
 - Doses up to 2 grams every 8 hours have been used and are indicated in areas where the local antibiogram indicates strains of *S. pneumoniae* not fully susceptible to penicillin.
 - If non-severe penicillin allergy (i.e., rash, unclear history), an effective oral cephalosporin is acceptable (i.e. cefdinir 300mg BID)
 - If severe penicillin allergy (i.e. anaphylaxis), please contact an Antimicrobial Stewardship Pharmacist Consultant for alternative antibiotic recommendation
- **Duration of treatment: 7 to 10 days**
 - Improvement should be seen within 48 to 72 hours. If there is no improvement, the patient should be reexamined and treated as below.

E. Antibiotic Therapy for Treatment Failure

- Treatment failure after 3 days of therapy indicates concern for drug-resistant *S. pneumoniae*.
- An agent with broader coverage than the initial therapy is recommended:
 - Amoxicillin-clavulanate XR 2000 mg/125 mg bid.
 - For patients with severe penicillin allergies, please contact a member of the Antimicrobial Stewardship Workgroup for alternative antibiotic recommendations.
- Duration of treatment after treatment failure is 10 days.
- Although levofloxacin and ceftriaxone may be viable therapy options, they should be reserved for ONLY those patients with absolute contraindications to amoxicillin-clavulanate.

F. References

- Limb, C. J., Lustig, L. R., & Durand, M. L. Acute otitis media in adults. In L. Kunins (Ed.), UpToDate. Retrieved March 1, 2022 from <https://www.uptodate.com/contents/acute-otitis-media-in-adults>
- Chambers, H. F. (2021) Otitis media, acute, empiric therapy. *Sanford Guide*. Retrieved March 1, 2022 from: <https://webedition.sanfordguide.com/en/sanford-guide-online/disease-clinical-condition/otitis-media>

7. PURULENT SKIN AND SOFT TISSUE INFECTIONS (SSTIs), INCLUDING MRSA

CONTENTS

A. Key Points	1
B. Culture and Sensitivity (C&S)	2
C. Empiric Treatment	3
D. References	4
E. Algorithm: Treatment of Purulent SSTIs	5
F. Incision and Drainage (I&D) Procedure	6
G. Inmate Fact Sheet—General Instructions for Skin Infections	9
H. Inmate Fact Sheet—Information on MRSA	10

A. Key Points

Purulent SSTIs include cutaneous abscesses, furuncles, carbuncles, folliculitis, and methicillin-resistant Staphylococcus aureus (MRSA).

- **CUTANEOUS ABSCESES** are collections of pus within the dermis and deeper skin tissues that are typically painful, tender, and fluctuant red nodules surrounded by inflamed tissue.
 - **FURUNCLES** (also known as **BOILS**) are infections of the hair follicle and adjacent tissue, forming a hard central core and pus that extends through the dermis into the subcutaneous tissue.
 - **CARBUNCLES** are similar to furuncles but involve several adjacent follicles that drain pus.
 - **FOLLICULITIS** is inflammation of the hair follicle that appears clinically as an eruption of *pustules* and/or *papules* centered upon hair follicles.

NOTE: The term “cellulitis” is NOT appropriate for cutaneous inflammation associated with collections of pus such as in septic bursitis, furuncles, or skin abscesses. *In such cases of purulent infection, the appropriate terminology is “with surrounding inflammation,” and NOT “with surrounding cellulitis.” This distinction is critical. The treatment of purulent infections is with incision and drainage (I&D), whereas the treatment of cellulitis is with antibiotics. (See [Chapter 8](#) for more about cellulitis and other non-purulent SSTIs.)*

- **COLONIZATION** is the presence of bacteria on or in the body without causing infection.
- **INCISION AND DRAINAGE (I&D)** is the recommended treatment for both non-MRSA and MRSA-suspected abscesses, carbuncles, and large furuncles not accompanied by systemic signs of infection.
 - The addition of systemic antibiotics to I&D does NOT improve cure rates in these cases.
 - Smaller furuncles often rupture and drain spontaneously or after treatment with moist heat (**WARM SOAKS AND COMPRESSES**).

- Systemic antibiotics are warranted in the presence of **SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS)**, indicated by temperature $>38^{\circ}\text{C}$ or $<36^{\circ}\text{C}$, tachypnea >24 breaths per minute, tachycardia >90 beats per minute, or white blood cell count $>12,000$ or <400 cells/ μL .
- **ORAL ANTIBIOTIC THERAPY** can be provided to patients with SSTIs that do not involve either significant cellulitic changes or signs/symptoms of systemic infection.
- **IV ANTIBIOTIC THERAPY** is needed for systemic infections, significant cellulitis, endocarditis and other endovascular infections, osteomyelitis, necrotizing fasciitis, pneumonia.
- **THE CAUSE FOR RECURRENT ABSCESES** at a particular site should be determined, including the possibility of a pilonidal cyst, hidradenitis suppurativa, or foreign material.
- **PATIENT EDUCATION** is crucial for effective treatment and the prevention of transmission of SSTIs. Inmate factsheets, [General Instructions for Skin Infections](#) and [Information on MRSA](#), are available in Sections G and H of this chapter.

B. Culture and Sensitivity (C&S)

- C&S results are used to direct and streamline therapy.
- Consider for moderate to severe infections, and those requiring IV therapy.
- Culturing of areas that are normally colonized is of little value. Culturing of wounds can often include normal skin flora. Samples should be taken from areas not normally colonized (e.g., wounds) by a clinician experienced in obtaining sterile cultures.
- Culture diagnosis should be obtained whenever clinically warranted, including:
 - For patients with recurrent SSTIs.
 - For an SSTI not resolving with current treatment.
 - As part of periodic surveillance to determine the predominant circulating pathogens in a given facility.
- Cultures from abscesses and other purulent SSTIs are recommended in the following cases:
 - If the provider believes antibiotic therapy is indicated for the patient.
 - For patients with severe local infection or signs of systemic illness.
 - For patients who have not responded adequately to initial treatment.
 - If there is concern for a cluster or outbreak.
- Positive diagnostic cultures include cultures from blood, sterile body fluids (e.g., joint fluid, pleural fluid, cerebrospinal fluid), expressed pus that avoids skin contamination, and aspirated abscess fluid.

C. Empiric Treatment

→ See [Treatment Algorithm](#) in Section E.

CONSERVATIVE AND MECHANICAL TREATMENT MEASURES

- The primary treatment of choice for cutaneous abscesses is I&D and/or warm compresses.
 - See Section F for [I&D Procedure](#) and see the [Treatment Algorithm](#) for information on using warm soaks and compresses.
- While smaller furuncles often rupture and drain spontaneously—or after treatment with moist heat—I&D is the recommended treatment for both non-MRSA and MRSA-suspected abscesses, carbuncles, and large furuncles not accompanied by systemic signs of infection.
 - An indication of the presence of pus in a bacterial skin infection is fluctuance: As the skin becomes infected, redness and induration (hardness) develop. If the pus does not drain, touching this area produces a soft, boggy feel known as fluctuance. In general, fluctuant lesions need to be incised and drained.
 - The addition of systemic antibiotics to I&D does not improve cure rates in these cases.
 - Once the abscess is drained, frequently reassess to determine whether repeated I&D is warranted.

ANTIBIOTIC THERAPY

★ *The decision to initiate antibiotic treatment should be based on [culture and sensitivity](#) results when possible. The use of antibiotics for the suspected presence of MRSA should be reserved for the following:*

- Single abscess ≥ 2 cm and/or multiple lesions
- Severe or extensive disease (e.g., involving multiple sites of infection) or rapid progression in the presence of associated cellulitis.
- Signs and symptoms of systemic illness.
- Associated comorbidities or immunosuppression (diabetes mellitus, HIV/AIDS, neoplasm).
- Extremes of age.
- Abscess in an area difficult to drain completely (e.g., face, hand, genitalia).
- Associated septic phlebitis.
- Lack of response to I&D alone.

DECOLONIZATION OF MRSA INFECTIONS

Decolonization is the use of antimicrobial or antiseptic agents to suppress or eliminate *S. aureus* to aid in preventing recurrent auto-infection or transmission to others.

- Decolonization is NOT routinely recommended.
- The efficacy of decolonization has NOT been well-established.

(continues on next page)

- **Two circumstances in which decolonization can be considered are described in the table below:**


Circumstances of MRSA Infection	Decolonization Procedure*
<ul style="list-style-type: none"> • INMATES WITH RECURRENT MRSA INFECTIONS (e.g., three or more infections in less than six months) • OUTBREAK SITUATIONS in which ongoing MRSA transmission is occurring among a well-defined cohort with close contact. <p>→ Requires consultation with Central Office infection control.</p>	<p>For 5–10 days:</p> <ul style="list-style-type: none"> • DAILY: Decontamination of personal items such as towels, sheets, and clothes; PLUS... • DAILY: Chlorhexidine washes; PLUS... • TWICE DAILY: 2% mupirocin ointment generously applied throughout the inside of both nostrils with a cotton swab. <p>→ Due to security concerns related to chlorhexidine formulations, the judicious use of chlorhexidine for decolonization is recommended on a case-by-case basis. Chlorhexidine formulations should NOT be dispensed directly to the inmate as a self-carry.</p>
<p>* Surveillance cultures following decolonization are NOT recommended in the absence of active infection.</p>	

D. References

- Gottlieb, M., DeMott, J. M., Hallock, M., & Peksa, G. D. (2019). Systemic antibiotics for the treatment of skin and soft tissue abscesses: A systematic review and meta-analysis. *Ann Emerg Med.* 73(1), 8-16. <https://doi.org/10.1016/j.annemergmed.2018.02.011>
- Baillargeon, J., Kelley, M. F., Leach, C.T., Baillargeon, G., & Pollock, B. H. (2004) Methicillin-resistant *Staphylococcus aureus* infection in the Texas prison system. *Clin Infect Dis.* 38(9), e92–e95. <https://doi.org/10.1086/383146>
- Boucher, H. W., & Corey, G. R. (2008) Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 46(supp 5), S344–349. <https://doi.org/10.1086/533590>
- Centers for Disease Control and Prevention. (2003) Methicillin-resistant *Staphylococcus aureus* infections in correctional facilities – Georgia, California, and Texas, 2001–2003. *MMWR.* 52(41), 992-996. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5241a4.htm>
- Dirksen, D. J. (2003) Incision and drainage of an abscess. In: J. L. Pfenninger & G.C. Fowler (Eds.), *Procedures for primary care physicians* (pp 50-53). St. Louis: Mosby.
- Downey, K. A., & Becker, T. (2021) Technique of skin abscess drainage. In M. Ganetsky (Ed.), *Up to Date*. Retrieved March 1, 2022 from <https://www.uptodate.com/contents/techniques-for-skin-abscess-drainage>
- Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S.L., Karchmer, A.W., Levine, D. P., Murray, B. E., Rybak, M. J., Talan, D. A., & Chambers, H. F. (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis.* 52(3), e18-e55. <https://doi.org/10.1093/cid/ciq146>
- Rybak, M. J., Lomaestro, B.M., Rotschafer, J.C., Moellering, R.C., Craig, W. A., Billeter, M., Dalovision, J. R., & Levin, D. P. (2009) Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis.* 49(3), 325-327. <https://doi.org/10.1086/600877>

- Stevens, D. L., Bisno, A. L., Chambers, H. F., Patchen Dellinger, E., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 59(2), e10-e52.
<https://doi.org/10.1093/cid/ciu444>

E. Algorithm: Treatment of Purulent SSTIs



DEFINITIONS:

MILD: No signs of systemic infection.

MODERATE: Systemic signs of infection.

SEVERE: Patients who have failed I&D plus oral antibiotics **OR** patients with systemic signs of infection plus hypotension (see [SIRS](#) in Section A).

I&D: Incision and drainage (see Section F for [I&D Procedure](#)).

C&S: Culture and sensitivity (see Section B for information on [C&S](#)).

MRSA: Methicillin-resistant *Staphylococcus aureus*

MSSA: Methicillin-sensitive *Staphylococcus aureus*

TMP/SMX: Trimethoprim/sulfamethoxazole

WARM SOAKS AND COMPRESSES:

- Soak the infected area in warm water for 20 minutes, 2–3 times a day or apply a heating pad or a warm, moist clean washcloth to the area for 20 minutes, 2–3 times a day.
- Decisions about how to safely implement warm soaks and/or compresses in the correctional setting must be made on a case-by-case basis, in consultation with the infection control officer.

ADAPTED FROM: Figure 1 in <http://cid.oxfordjournals.org/content/early/2014/06/14/cid.ciu296.full.pdf+html>

NOTE: Providers should consult with a pharmacist for assistance with medication selection, specific dosing recommendations, and medication monitoring.

F. Incision and Drainage (I&D) Procedure

Abscesses are localized infections of tissue marked by a collection of pus surrounded by inflamed tissue. Abscesses may be found in any area of the body, but most abscesses presenting for urgent attention are found on the extremities, buttocks, breast, perianal area, axilla, groin, or hair follicles (furuncles and carbuncles). Abscesses begin when the normal skin barrier is breached, and microorganisms colonize the underlying tissues. Causative organisms commonly include *Streptococcus sp.*, *Staphylococcus sp.*, enteric bacteria (perianal abscesses), or a combination of anaerobic and gram-negative organisms.

Abscesses resolve by drainage:

- Smaller abscesses may resolve with conservative measures (see description of [warm soaks](#) above in the Algorithm) to promote spontaneous drainage.
- Larger abscesses will require incision to drain them (I&D), since the increased inflammation, pus collection, and walling-off of the abscess cavity diminish the effectiveness of antibiotic treatment. Healing following an I&D should progress from the inside of the abscess outward to the incision site. This will require a gauze packing to promote healing from the inside outward.

INDICATION FOR I&D

Abscess within the skin that is palpable.

CONTRAINDICATIONS FOR I&D

- Extremely large abscesses that require extensive incision, debridement, or irrigation—best done in operating room.
- Deep abscesses in very sensitive areas (labial, supraleator, ischioanal, perirectal)—require a general anesthetic to obtain proper exposure.
- Abscess in the hands or feet.
- Abscesses in the triangle formed by the bridge of the nose and the corners of the mouth—should generally be treated with warm compresses and aggressive antibiotic therapy.
- Abscesses located near major vessels—must be differentiated from aneurysms before I&D is performed, to avoid fatal hemorrhage. The distinction is made through aspiration with a large bore needle.

MATERIALS

- Sterile gloves
- Mask/eye protection, if abscess appears to be under pressure enough to cause expulsion of contents with the incision
- Local anesthesia: 1% or 2% lidocaine with epinephrine; 10 cc syringe and 23-gauge needle for infiltration. (*Note: Epinephrine is contraindicated in areas such as the fingers, nose, toes, and penis*). Alternatively, diphenhydramine (Benadryl) 10 to 25 mg can be used for anesthesia. Dilute a 50 mg (1 cc) vial in a syringe with 4 cc of normal saline.
- Alcohol or povidone-iodine wipes
- #11 scalpel blade with handle
- Draping
- Hemostat or sterile cotton-tipped applicator

(list of I&D materials continued on next page)

- Packing (plain or iodoform, ½" or ¼" packing)
- Scissors
- Gauze and tape
- Culture swab (aerobic and anaerobic)

PRE-PROCEDURE EDUCATION

- Obtain informed consent. Inform the patient of potential severe complications and their treatment.
- Explain the steps of the procedure, including the pain associated with anesthetic infiltration.

I&D PROCEDURE

1. Use Standard Precautions.
2. Cleanse site over abscess with skin preparation of choice.
3. Drape to create a sterile field.
4. Infiltrate local anesthetic, allowing 2–3 minutes for anesthetic to take effect.
5. Incise over abscess with the #11 blade, cutting through the skin into the abscess cavity. Follow skin fold lines whenever possible while making the incision. The incision should be sufficiently wide to allow the abscess to drain and to prevent premature closure of the incision.
For smaller abscesses requiring incisions, a “stab” or “cruciate” incision should be adequate. Some refer to this as a puncture or stab technique since the operator inserts the tip of the scalpel directly into the center of the abscessed tissue without making a linear incision.
6. Allow the pus to drain, using the gauzes to soak up drainage and blood. If a culture is being obtained, use the culture swab to take culture of abscess contents, swabbing inside the abscess cavity—NOT from the superficial skin over the abscess.
7. Use the hemostat or sterile cotton-tipped applicator to gently explore the abscess cavity to break up any locations within the abscess.
8. Loosely pack the abscess cavity with the packing.
9. Place gauze dressing over the wound, and tape in place (without placing tape over the incision site).
10. Remove gloves and wash hands. Properly dispose of contaminated articles and assure appropriate cleaning of the area.
11. Schedule a call-out within 24–48 hours post-op. Depending upon the location and size of the abscess, arrange for the packing material to be changed daily or several times per day.
12. Pain from the site may require acetaminophen or nonsteroidal anti-inflammatory drugs; narcotics are rarely needed. With a tense abscess, the pain relief associated with the I&D itself may be sufficient so no pain medication is required.

POST-PROCEDURE PATIENT EDUCATION

→ An [Inmate Fact Sheet—General Instructions for Skin Infections](#) is available in Section G.

Symptoms: Patients should be instructed to watch for the following, and be advised to seek medical attention if they experience such symptoms:

- Re-collection of pus in the abscess
- Fever and chills
- Increased pain and redness
- Red streaks near the abscess
- Increased swelling

Self-care: While some inmates will need to return to the clinic to have their dressings changed, others can be taught to do this for themselves. In addition to showing these patients how to change the packing and replace the dressings, they should be educated on:

- Disposal of dressing material
- Hand-washing technique
- Cleansing the area after the dressing is complete

I&D COMPLICATIONS

Prevention and management of complications associated with I&D are outlined below.

Complication	Prevention/Cause	Management
Insufficient anesthesia	Keep in mind the tissue around an abscess is acidotic, and local anesthetic loses effectiveness in acidotic tissues.	<ul style="list-style-type: none"> • Do a field block. • Use sufficient quantity of anesthetic. • Allow time for anesthetic effect.
No drainage	Localize site of incision by palpation.	Extend incision deeper or wider as needed.
Drainage is sebaceous material	Abscess was an inflamed sebaceous cyst.	<ul style="list-style-type: none"> • Express all material. • Break up sac with hemostat. • Pack open, as with an abscess.

- Following I&D of any abscess, the site should be observed for signs of re-collection of pus or cellulitis.
- Complications of an inadequately treated abscess include bacteremia and septicemia.
- In persons who are immunocompromised, particularly diabetics, an abscess on an extremity can be complicated by severe cellulitis or gangrene, with potential loss of the affected extremity.
- An I&D of a perianal abscess frequently results in a chronic anal fistula that requires fistulectomy by a surgeon.
- Deep palmar abscesses are a surgical emergency.

DOCUMENTATION OF I&D ON THE MEDICAL RECORD

- Informed consent (signed).
- Procedure used, prep, anesthetic (type and quantity), success of drainage, culture if collected.
- Any complications (or “none”).
- Who was notified of any complication (APP, attending MD).
- Follow-up arrangements for scheduled call-out and dressing changes.

G. Inmate Fact Sheet—General Instructions for Skin Infections

Handwashing and General Hygiene
<ul style="list-style-type: none">• Regularly wash your hands with soap and water for at least 15 seconds, <i>especially</i>:<ul style="list-style-type: none">➤ Before and after using the toilet➤ Before and after touching your wound➤ Before eating• Shower frequently and put on clean clothes. Change your clothing whenever they become soiled with wound drainage.• Change bed linens and towels regularly and whenever they become soiled with wound drainage.• Do <i>not</i> share personal items such as razors, towels, wash cloths, bars of soap, etc.• If you have an open wound, it should be covered at <i>all</i> times with a bandage.• Do not allow other inmates to touch your wound.• If your bandage comes off, dispose of it carefully in a leak-proof container as instructed by health services staff. Then, wash your hands. Inform a correctional worker you need a new bandage.• You cannot work in Food Service if you have a draining wound on your hands, or if you have wounds located elsewhere and wound drainage is not contained by a bandage.
Warm Soaks and Compresses
You may be instructed to soak your skin infection regularly in warm salt water, or apply moist compresses for 20 minutes at a time. Carefully follow the instructions you receive. If your wound begins to drain, report it to the health center.
Antibiotics
Take all medications prescribed by your doctor—exactly as you are told.
Report <i>any</i> of the following to the health center:
<ul style="list-style-type: none">• Fever• Red streaks up from the wound• Increased foul smell from wound drainage• Increased wound drainage

H. Inmate Fact Sheet—Information on MRSA

What is MRSA?
<ul style="list-style-type: none">• <i>Staphylococcus aureus</i>, often referred to as “staph,” is a common type of bacteria found on the skin and in the nose of healthy persons. Staph bacteria may cause minor skin infections such as boils, or more serious infections such as pneumonia and blood poisoning.• Certain “staph” bacteria have become resistant to the usual “first-line” antibiotics are called MRSA—which is short for “methicillin-resistant <i>Staphylococcus aureus</i>.” MRSA infections are more difficult to treat, but they usually respond to “incision and drainage” and/or stronger antibiotics.
How is MRSA spread from person to person?
<ul style="list-style-type: none">• MRSA is usually spread through direct physical contact with an infected person but may also be transmitted through contact with contaminated objects or surfaces.• MRSA is NOT spread by coughing unless the infected person has pneumonia.
How can you prevent becoming infected with MRSA?
<ul style="list-style-type: none">• Wash your hands thoroughly with soap and water throughout the day, particularly every time you use the toilet and before every meal.• Never touch another person’s wounds, infected skin, or dirty bandages.• Don’t scratch skin rashes.• Maintain personal hygiene through regular showers and by keeping your living space clean, including regularly laundering your bed linens.• Do not hand-wash and air dry your laundry. Use the institutional laundry.• Never share personal hygiene items with others, including toiletries or towels.• Clean off any surfaces shared with others, such as weight benches.• Use a towel or shirt as a barrier between your bare skin and exercise equipment.• Shower after participating in close-contact recreational activities whenever possible.• Don’t get a tattoo in prison.• Don’t use injection drugs.• Don’t have sexual contact with other inmates.• Shower before participating in sweat lodges and wear clean clothes. Then, shower after the sweat lodge.
How do you know if you have a MRSA infection?
<ul style="list-style-type: none">• Always seek medical attention if you develop a boil, red or inflamed skin, an infected insect or spider bite, or a sore that does not go away.• The most common way for health care providers to detect MRSA is by doing a culture of the pus from the skin infection.
How is MRSA treated?
<ul style="list-style-type: none">• MRSA skin infections are often treated first with frequent warm soaks and draining of the wound.• Strong antibiotics can be effective in treating MRSA.• Serious or highly resistant MRSA infections may require intravenous (IV) antibiotics in the hospital.

8. NON-PURULENT SKIN AND SOFT TISSUE INFECTIONS (SSTIs)

CONTENTS

A. Key Points	1
B. References	2
C. Algorithm: Treatment of Non-Purulent SSTIs	3

A. Key Points

Non-purulent SSTIs include **CELLULITIS**, **ERYSIPELAS**, and **NECROTIZING INFECTION**.


- **CELLULITIS** and **ERYSIPELAS** refer to diffuse, superficial, spreading skin infections. These infections cause rapidly spreading areas of erythema, swelling, tenderness, and warmth, and are caused by a bacterial breach in the skin.
 - **ERYTHEMA** is blanchable redness of the skin, which can be localized or generalized, and is caused by dilation of superficial blood vessels and capillaries near the skin's surface.
 - **The term CELLULITIS is NOT appropriate for cutaneous inflammation associated with collections of pus such as in septic bursitis, furuncles, or skin abscesses.**
 - In such cases of purulent infection, the appropriate terminology is “**with surrounding inflammation**” and NOT “with surrounding cellulitis.”
 - ★ **This distinction is critical.** The treatment of purulent infections is with incision and drainage (I&D), whereas the treatment of cellulitis is with antibiotics. (See [Chapter 7](#) for information on the treatment on purulent SSTIs.)
 - Typical cases of cellulitis should include an antibiotic active against streptococci.
 - In cases of uncomplicated cellulitis, a 5-day course of antimicrobial therapy is adequate but may extend to 14 days if severe infection, slow response to therapy, or immunosuppression
 - Methicillin-resistant *Staphylococcus aureus* (MRSA) coverage is recommended when there are systemic signs of toxicity (fever, hypotension, etc.), prior episode of MRSA infection or colonization, recent hospitalization, residence in a long term care, hemodialysis, or HIV.
 - Use of nonsteroidal anti-inflammatory drugs or corticosteroids are not favored as they could mask signs and symptoms of inflammation and delay diagnosis/treatment. While some studies may show NSAIDs shorten time to regression of inflammation and corticosteroids may be associated with a shorter median healing time, these are limited by a small sample size.
 - 22-40% of patients report recurrent cellulitis. 14% of cases recur within 1 year, while 45% of cases recur within 3 years. The approach to management for a recurrent episode is the same as the initial episode.
 - If patients experience 3-4 episodes within 1 year, suppressive therapy may be warranted if the predisposing factors/cause cannot be removed. Suspected beta-hemolytic strep infections should be treated with penicillin VK, erythromycin or penicillin G while staph infections should utilize cefadroxil, clindamycin or TMP-SMX.

- **NECROTIZING INFECTIONS** are deep infections involving fascial and/or muscle compartments and causing major tissue destruction. The initial presentation is of cellulitis, which can advance rapidly or slowly. As it progresses, there is systemic toxicity including high temperatures, disorientation, and lethargy.
★ *A distinguishing feature is the wooden-hard induration of the subcutaneous tissues.*

B. References

- Thomas, K. S., Crook, A. M., Nunn, A. J., Foster, K. A., Mason, J. M., Chalmers, J. R., Nasr, I. S., Brindle, R. J., English, J., Meredith, S. K., Reynolds, N. J., de Berker, D., Mortimer, P. S., Williams, H. C., & U.K. Dermatology Clinical Trials Network's PATCH I Trial Team. (2013) Penicillin to prevent recurrent leg cellulitis. *N Engl J Med.* 368(18), 1695-1703.
<https://www.nejm.org/doi/10.1056/NEJMoa1206300>
- Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S.L., Karchmer, A.W., Levine, D. P., Murray, B. E., Rybak, M. J., Talan, D. A., & Chambers, H. F. (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis.* 52(3), e18-e55. <https://doi.org/10.1093/cid/ciq146>
- Stevens, D. L., Bisno, A. L., Chambers, H. F., Patchen Dellinger, E., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 59(2), e10-e52.
<https://doi.org/10.1093/cid/ciu444>
- Raff, A. B., & Kroshinsky, D. (2016) Cellulitis: A Review. *JAMA.* 316(3), 325-37.
<https://doi.org/10.1001/jama.2016.8825>
- Spelman, D., & Baddour, L. M. (2021) Celulitis and skin abscess in adults: Treatment. In K. K. Hall (Ed.), *Up to Date*. Retrieved March 1, 2022 from
<https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment>
- Spelman, D., & Baddour, L. M. (2021) Celulitis and skin abscess in adults: Epidemiology, microbiology, clinical manifestations, and diagnosis. In K. K. Hall (Ed.), *Up to Date*. Retrieved March 1, 2022 from
<https://www.uptodate.com/contents/cellulitis-and-skin-abscess-epidemiology-microbiology-clinical-manifestations-and-diagnosis>
- Fabre, V., & Bartlett, J. G. (2019) Cellulitis. *Johns Hopkins Antibiotic (ABX) Guide*. Available at:
https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540106/all/Cellulitis

C. Algorithm: Treatment of Non-Purulent SSTIs



DEFINITIONS:
MILD: Typical cellulitis/erysipelas without systemic signs of infection
MODERATE: Typical cellulitis/erysipelas with systemic signs of infection.
SEVERE: Patients who have failed oral antibiotic treatment; or who have systemic signs of infection; or who are immunocompromised; or who have clinical signs of deeper infection such as bullae, skin sloughing, hypotension, or evidence of organ dysfunction.
C&S: Culture and sensitivity.
Adapted from: Figure 1 in <http://cid.oxfordjournals.org/content/early/2014/06/14/cid.ciu296.full.pdf+html>

9. CLOSTRIDIUM DIFFICILE INFECTION

CONTENTS

A. Key Points	1
B. Diagnosis	2
C. Classification of Severity	2
D. Treatment	3
E. Infection Control and Prevention.....	4
F. References.....	4

A. Key Points

- **CLOSTRIDIUM DIFFICILE (C. DIFFICILE)** is a spore-forming, toxin-producing, gram-positive anaerobic bacterium that colonizes the human intestinal tract after the normal gut flora has been disrupted (frequently in association with antibiotic therapy).
- **C. DIFFICILE INFECTION (CDI)** *C. difficile* infection (CDI) is one of the most common health care-associated infections and a significant cause of morbidity and mortality, especially among older adult hospitalized patients. CDI can cause a spectrum of manifestations ranging from an asymptomatic carriage to fulminant disease with toxic megacolon.
- **PRIMARY RISK FACTORS** for CDI include the following:
 - **Antibiotic exposure:** Frequently associated with use of clindamycin, fluoroquinolones, broad spectrum penicillins, second- or higher-generation cephalosporins, and carbapenems; Occasionally associated with macrolides (i.e., azithromycin, clarithromycin), narrow spectrum penicillins, first generation cephalosporins, trimethoprim-sulfamethoxazole, and sulfonamides.
 - ★ *If CDI is suspected or diagnosed, any antibiotics potentially contributing to the development of CDI should be discontinued unless they are absolutely indicated.*
 - **Exposure to the organism itself**
 - **Other notable risk factors:** Use of acid-lowering medications (e.g., omeprazole, ranitidine, etc.), cancer chemotherapy, gastrointestinal surgery, gastrointestinal tract manipulation, comorbid conditions (e.g., inflammatory bowel disease, immunosuppression, cirrhosis, pregnancy), age >65, current or recent hospital admission, and duration of stay in hospital or long-term care facility.
- **EMPIRIC CDI TREATMENT may be considered**, regardless of laboratory test result, in the context of high clinical suspicion—due to risk of a false negative or for situations where a substantial delay in laboratory confirmation is expected
- **SYMPTOMATIC TREATMENT with anti-peristaltic medications (e.g., loperamide) and opiates should be avoided**, as they can precipitate severe disease and potentially mask symptoms, thereby interfering with the monitoring of CDI resolution.
- **LABORATORY CONFIRMATION of cure should NOT be performed.** False positives are common, complicating care and contributing to inappropriate antibiotic use.

- **RECURRENT *C. DIFFICILE* INFECTION (RCDI)** is thought to be largely linked to altered colonic microbiota. 10–20% of patients with CDI will suffer RCDI within 8 weeks of completing the initial CDI treatment regimen. Of these patients, the rates of further recurrence range from 40–65%. Identification of RCDI is necessary to select appropriate treatment, particularly beyond the first recurrence. (See more information in the table under [Treatment](#) below.)
- **USE OF PROBIOTICS** is discussed in [Chapter 10](#) of the *Antimicrobial Stewardship Clinical Guidance*.

B. Diagnosis

DIAGNOSIS is made after pre-screening for symptoms (unexplained and new onset of ≥ 3 unformed stools in 24 hours) and risk factors.

- **DIFFERENTIAL DIAGNOSIS** of *C. difficile* must be distinguished from other infectious and noninfectious causes of diarrhea (i.e., acute abdomen, shock, infectious diarrhea caused by other organisms, post-infectious irritable bowel syndrome, inflammatory bowel disease, microscopic colitis, and celiac disease).
- **TESTING** of stools (prior to initiating antibiotic therapy) from patients with diarrhea should be done by utilizing one of the following methods:
 - **NUCLEIC ACID AMPLIFICATION TEST (NAAT)** for toxigenic *C. difficile* (e.g., PCR assay)
 - ★ *Use only in the context of unexplained documented diarrhea, due to risk of unnecessary treatment of asymptomatic positives.*
 - **GLUTAMATE DEHYDROGENASE SCREENING TEST**, followed by confirmation with either NAAT or toxin A + B enzyme immunoassay (EIA)
 - ★ *NAAT may be preferred for confirmation, due to higher sensitivity than EIA.*
 - Repeat testing for test of cure is not indicated; stool assays may remain positive during or after clinical recovery

C. Classification of Severity

CLASSIFICATION OF SEVERITY is necessary in order to select the appropriate treatment.

- **MILD TO MODERATE DISEASE:**
 - WBC $\leq 15,000$ cells/mL **and**
 - SCr < 1.5 mg/dL or no increase in serum creatinine
- **SEVERE:**
 - WBC $> 15,000$ cells/mL, **and/or**
 - SCr ≥ 1.5 mg/dL or $\geq 50\%$ increase in serum creatinine
 - Zar score ≥ 2

ZAR SCORE FACTORS	POINTS(s)
Age > 60 years	1
Body temperature $> 38.3^{\circ}\text{C}$ (100.1°F)	1
Albumin < 2.5 g/dL	1
WBC $> 15,000$ cells/mL	1
Endoscopic evidence of pseudomembranous colitis	2
Treatment in ICU	2

D. Treatment

Severity	Treatment	Comments
Initial episode: MILD TO MODERATE	<ul style="list-style-type: none"> • Vancomycin 125mg po qid for 10 days. • Fidaxomicin 200mg po bid for 10 days¹ • If above agents unavailable: Metronidazole 500mg po tid for 10 days for mild disease only.² 	<ul style="list-style-type: none"> • If possible, STOP antibiotics that may be contributing to CDI development.
Initial episode: SEVERE	<ul style="list-style-type: none"> • Vancomycin 500mg po qid AND metronidazole 500mg IV every 8 hours. • If ileus is present: Add vancomycin 500mg in 100ml normal saline per rectum every 6 hours as a retention enema. 	<ul style="list-style-type: none"> • Surgical consult is recommended. • If possible, STOP antibiotics that may be contributing to CDI development.
RECURRENT EPISODE (first recurrence) *** (within 8 weeks of completing prior treatment)	<p>Use a regimen different from original, if possible:</p> <ul style="list-style-type: none"> • Prolonged tapered/pulsed vancomycin regimen: Vancomycin 125mg po qid x 10 days, then 125 mg po tid x 1 week, then 125 mg po bid x 1 week, then 125 mg qd x 1 week, then 125 mg every other day x 1 week, then 125 mg every third day x 1 week • Fidaxomicin 200mg po bid x 10 days (standard); or 200mg po bid x 5 days, then every other day x 20 days (extended) • If metronidazole was used for initial episode: Vancomycin 125mg po qid for 10 days 	<ul style="list-style-type: none"> • Confirm level of severity • If possible, STOP antibiotics that may be contributing to CDI development
RECURRENT EPISODE (multiple) or PROPHYLAXIS (recurrence within 6 months)	<ul style="list-style-type: none"> • Discussion of patients with multiple recurrent CDIs is beyond the scope of this CGD and should be managed on a case-by-case basis and consultation with a specialist should be considered. Possible treatment may include pulsed and/or tapered regimens, with or without rifaximin or fidaxomicin “chasers,” fecal microbiota transplant (FMT), and use of bezlotuxamab IV. 	
<p>¹ A 10-day course of fidaxomicin 200mg po twice a day may be considered INSTEAD of vancomycin regimen in patients with moderate, uncomplicated infection who are at particularly high risk of recurrence (e.g., when causative antibiotic cannot be discontinued).</p> <p>² Metronidazole should only be used for an initial episode of mild CDI, and only if vancomycin and fidaxomicin are unavailable.</p> <p>Note: Oral vancomycin doses may be compounded from the intravenous formulations at capable institutions at significant cost savings.</p>		

E. Infection Control and Prevention

- Accommodate patients with CDI in a private room with a dedicated toilet to decrease transmission to other patients. If there is a limited number of private single rooms, prioritize patients with stool incontinence for placement in private rooms
- Patients with suspected CDI should be placed on preemptive contact precautions pending the *C. difficile* test results if test results cannot be obtained on the same day. Contact precautions should be maintained for all CDI patients for at least 48 hours after diarrhea has resolved.
- Gloves and gowns must be worn by all individuals entering the room of any CDI patient, and removed before exiting.
- Hand hygiene should be performed before and after caring for a patient with *C. difficile* by using soap and water. Alcohol-based and chlorhexidine-based sanitizers are **NOT** effective against *C. difficile* spores.
- Daily and terminal disinfection of environmental surfaces should be performed with a *C. difficile*-sporicidal disinfectant during outbreaks or in hyperendemic (sustained high rates) settings, or if there is evidence of repeated cases of CDI in the same room.
- There is not enough evidence to show that probiotics prevent CDI. See [Chapter 10](#) of this *Antimicrobial Stewardship Clinical Guidance* for more information on probiotics.

F. References

- Burgos, R., & Schmiedeskamp-Rahe, M. (2016). Selected infections of the GI tract and liver. In: Murphy J. E., & Lee, M.W. (Eds.) *Pharmacotherapy self-assessment program, 2016 book 2: GI/fluids and nutrition* (10-12). American College of Clinical Pharmacy.
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Sammons, J. S., Sandora, T. J., & Wilcox, M. H. (2018) Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clinical Infectious Diseases*, 66(7), e1-e48. <https://doi.org/10.1093/cid/cix1085>
- Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013). Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol*, 108(4), 478-498. [doi: 10.1038/ajg.2013.4](https://doi.org/10.1038/ajg.2013.4)

10. PROBIOTICS

CONTENTS

A. Key Points	1
B. References	2

A. Key Points

- Microbiological studies and current literature suggest an alteration or imbalance in gastrointestinal (GI) bacteria may be causative in *Clostridium difficile* (*C. difficile*) infections and may cause symptoms in individuals with inflammatory bowel disease (IBD).
- The Food and Drug Administration (FDA) classifies probiotics as supplements. As such, their content and dose vary from brand to brand. According to the FDA, “supplements are not intended to treat, diagnose, prevent, or cure diseases.”
- A large percentage of trials studying probiotic use did not report or inadequately reported harm data, thus the safe use to probiotics cannot be assumed without this data.
- Studies suggest probiotic use may affect the microbiome by delaying post antibiotic gut mucosal recovery (The clinical significance of this is uncertain and needs more research)

C. DIFFICILE

- Routine probiotic use for prevention or treatment of *C. difficile* is not recommended.
- Several studies have investigated the use of probiotics for treatment and prevention. However, current literature is inconsistent, and no strong evidence supports routine probiotic use for prevention or treatment.

INFLAMMATORY BOWEL DISEASE

- Available literature does not support probiotic supplementation for treatment of Crohn’s disease at this time.
- While there are small studies that reflect there may be a benefit with certain strains of probiotics in ulcerative colitis, the data is weak and remains unproven.

B. References

- Bafeta, A., Koh, M., Riveros, C., & Ravaud, P. (2018) Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systemic Review. *Ann Intern Med*, 169(4), 240-247. <https://doi.org/10.7326/M18-0343>
- Derikx, L. A. A. P., Dieleman, L. A., & Hoentjen, F. (2016) Probiotics and prebiotics in ulcerative colitis. *Best Pract Res Clin Gastroenterol*, 30(1), 55–71. <https://doi.org/10.1016/j.bpg.2016.02.005>
- Evans, C.T., & Johnson, S. (2015) Prevention of *Clostridium difficile* infection with probiotics. *Clin Infect Dis*, 60(supp 2), s122-s128. <https://doi.org/10.1093/cid/civ138>
- Ghouri, Y. A., Richards, D. M., Rahimi, E. F., Krill, J. T., Jelinek, K. A., & DuPont, A. W. (2014) Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in

inflammatory bowel disease. *Clin Exper Gastroenterol*, 7, 473-487.

<https://doi.org/10.2147/CEG.S27530>

- Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., Guyatt, G. H., & Johnston, B. C. (2013) Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database Syst Rev*. 2013(5). <https://doi.org/10.1002/14651858.CD006095.pub3>
- Hempel, S., Newberry, S. J., Maher, A. R., Wang, Z., Miles, J. N. V., Shanman, R., Johnsen, B., & Shekelle, P. G. (2012) Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA*, 307(18), 1959-1969 [doi:10.1001/jama.2012.3507](https://doi.org/10.1001/jama.2012.3507)
- Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. *Drugs*, 72(6), 803–823. <https://doi.org/10.2165/11632710>
- Johnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) Probiotics for the prevention of *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Ann Intern Med*, 157(12), 878-888. <https://doi.org/10.7326/0003-4819-157-12-201212180-00563>
- Lau, C. S.M., & Chamberlain, R. S. (2016) Probiotics are effective at preventing *Clostridium difficile*-associated diarrhea: a systematic review and meta-analysis. *Int J Gen Med*, 2016(9), 27-37. <https://doi.org/10.2147/IJGM.S98280>
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Sammons, J. S., Sandora, T. J., & Wilcox, M. H. (2018) Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clinical Infectious Diseases*, 66(7), e1-e48. <https://doi.org/10.1093/cid/cix1085>
- Naidoo, K., Gordon, M., Fagbemi, A. O., Thomas, A. G., & Akobeng, A. K. (2011) Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev*, 2011(12). <https://doi.org/10.1002/14651858.CD007443.pub2>
- Ollech, J. E., Shen, N. T., Crawford, C. V., & Ringel, Y. (2016) Use of probiotics in prevention and treatment of patients with *Clostridium difficile* infection. *Best Prac & Res Clin Gastroenterol*, 30(1), 111-118. 2016;30:111–118. <https://doi.org/10.1016/j.bpg.2016.01.002>
- Su, G. L., Ko, C. W., Bercik, P., Falck-Ytter, Y., Sultan, S., Weizman, A. V., Morgan, R. L. (2020) AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. *Gastroenterology*, 159(2), 697-705. <https://doi.org/10.1053/j.gastro.2020.05.059>
- Suez, J., Zmora, N., Ziberman-Schapira, G, Mor, U., Dori-Bachash, M., Bashiardes, S., Zur, M., Regev-Lehavi, D., Ben-Zeev Brik, R., Federici, S., Horn, M., Cohen, Y., Moor, A. A., Zeevi, D., Korem, T., Kotler, E., Harmelin, A., Itzkovitz, S., Maharshak, N., ... Elinav, E. (2018) Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired By Probiotics and Improved by Autologous FMT. *Cell*, 174(6), 1406-1423. <https://doi.org/10.1016/j.cell.2018.08.047>
- Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol*, 108(4), 478–498. [doi:10.1038/ajg.2013.4](https://doi.org/10.1038/ajg.2013.4)
- Zigra, P. I., Maipa, V. E., & Alamanos, Y.P. (2007) Probiotics and remission of ulcerative colitis: a systematic review. *Neth J Med*, 65(11), 411-418. Retrieved March 1, 2022, from <https://www.njmonline.nl/getpdf.php?id=600>

11. URINARY TRACT INFECTIONS

CONTENTS

A. Key Points	1
B. Culture and Urinalysis	2
C. Outpatient Treatment.....	3
D. References	3
E. Recommended Procedure for Using Urinary Catheter (Indwelling Foley) for Collecting Urine for Culture	4

A. Key Points

Bacterial presence in the genitourinary system is classified into three distinct areas:

- **ASYMPTOMATIC BACTERIURIA**
 - Asymptomatic patients with positive cultures have either asymptomatic bacteriuria or a contaminated urine specimen. See Chapter 12 [Asymptomatic Bacteriuria](#).
- **UNCOMPLICATED CYSTITIS AND PYELONEPHRITIS**
 - Uncomplicated urinary tract infection occurs in a patient who does not have an underlying condition that increases the risk of failing therapy. The infection can occur in the upper or lower urinary track.
- **CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI)**
 - Catheterized patients will become colonized within 48 hours of catheterization, this does not necessarily indicate infection requiring treatment.
 - CAUTI should be confirmed by the presence of bacteria *and* elevated white blood cells in the urinalysis, together with systemic signs of infection.
 - The CDC’s National Healthcare Safety Network recommends the Foley catheter be changed prior to obtaining a culture if the Foley has been in place for 14 days or longer. (See [References](#).)
 - An in-depth discussion of CAUTI is outside the scope of this guidance, but antimicrobial therapy is generally adjuvant to non-pharmacologic intervention, including catheter removal and routine reevaluation of continued need for catheter use. Consult with an infection control nurse for more information.

B. Culture and Urinalysis

- Urine culture must always be interpreted in the context of a urinalysis and patient symptoms.
- Urine culture should be collected prior to the initiation of antibiotic therapy, and used to narrow the empiric antimicrobial regimen
- **Women:** Urine culture is not required for the treatment of women with uncomplicated cystitis (i.e., absence of fever, flank pain, or other suspicion for pyelonephritis), unless the patient has recurrent urinary tract infections, is immunocompromised, or has other comorbid complications.
- **Men:** Culture is always warranted for the evaluation of men presenting with symptoms of cystitis.
- **Using indwelling catheters for urine cultures:**
 - Clinical staff should aseptically utilize the collection (sampling) port.
 - **Appropriate for:** Local findings suggestive of CAUTI, evaluation of sepsis without a clear source, prior to certain urologic procedures, early pregnancy.
 - **Not appropriate (due to concerns regarding urine quality) for:** Screening patients for infection, asymptomatic elderly patients, diabetics, or documenting clearing of bacteria.
- Providers should deliver samples within the timeframe as directed by the laboratory

INDICATORS OF INFECTION ON A URINALYSIS: In the presence of symptoms of a urinary tract infection (such as dysuria, urinary frequency/urgency, suprapubic pain) the following results are indicators of infection:

TEST	NORMAL RANGE	INDICATOR OF INFECTION
Bacteria	Absent	Any amount
White Blood Cells	< 5 cells	>10 cells
Leukocyte Esterase	Absent	Positive (indicates presence of white blood cells in urine)
Nitrite	Absent	Positive (nitrate-reducing microorganisms only, such as E. coli)
pH	4.5-8	pH is increased if urea-splitting organism is present (Klebsiella, Proteus)
Appearance	Clear	Cloudy/turbid (non-catheterized patients ONLY)

C. Outpatient Treatment

- Empiric regimens should be guided by local resistance patterns when available.
- Antimicrobial regimens should be tailored based on culture and sensitivity (C&S) results utilizing an active agent with the narrowest spectrum of activity.

FIRST-LINE EMPIRIC REGIMENS FOR WOMEN

- **Uncomplicated cystitis** (absence of fever, flank pain, or other suspicion for pyelonephritis):
 - Nitrofurantoin 100mg po bid for 5 days *OR*
 - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 3 days (if local resistance rates are > 20%, use of alternative agent is recommended)
- **Acute pyelonephritis** (fever > 99.9 °F, flank pain, costovertebral angle tenderness, other signs of systemic illness; obtain C&S prior to initiation):
 - Ciprofloxacin 500mg po bid for 7 days *OR*
 - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 14 days (with single loading dose of intravenous ceftriaxone or aminoglycoside if susceptibility is unknown)

FIRST-LINE EMPIRIC REGIMENS FOR MEN

- **Acute simple cystitis** (dysuria, frequency, urgency, +/- suprapubic pain, - symptoms of bladder outlet obstruction; obtain C&S prior to initiation)
 - Nitrofurantoin 100mg po BID for 7 days *OR*
 - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 7 days
- **Acute complicated cystitis** (suspected prostatic involvement, underlying bladder dysfunction; obtain C&S prior to initiation)
 - Ciprofloxacin 500mg po BID for 7 days
- **Acute pyelonephritis** (fever > 99.9 °F, flank pain, costovertebral angle tenderness, other signs of systemic illness; obtain C&S prior to initiation)
 - Ciprofloxacin 500mg po bid for 14 days
 - Sulfamethoxazole/trimethoprim 800mg/160mg po bid for 14 days
- ★ *A 14-day duration is recommended for patients presenting with fever because febrile UTI is often associated with prostatic involvement.*

D. References

- Centers for Disease Control and Prevention. (2021) *National Healthcare Safety Network Long-term Care Facility Component: Urinary Tract Infection (UTI) Event for Long-term Care Facilities.* <https://www.cdc.gov/nhsn/pdfs/ltc/lctf-uti-protocol-current.pdf>
- Association for Professionals in Infection Control and Epidemiology (n.d.) *Guide to Preventing Catheter-Associated Urinary Tract Infections.* <https://apic.org/Resources/Topic-specific-infection-prevention/Catheter-associated-urinary-tract-infection>
- Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*, 52(5), e103–e120. <https://doi.org/10.1093/cid/ciq257>

- Hooton, T. M., Bradley, S. F., Cardenas, D. D., Colgan, R., Geerlings, S. E., Rice, J. C., Saint, S., Schaeffer, A. J., Tambayh, P. A., Tenke, P., & Nicolle, L. E. (2010) Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*, 50(5), 625-663. <https://doi.org/10.1086/650482>
- Hooton, T. M., & Gupta, K. (2021) Acute simple cystitis in women. In: A. Bloom (Ed.), *UpToDate*. Retrieved March 1, 2022, from <https://www.uptodate.com/contents/acute-simple-cystitis-in-women>
- Hooton, T. M. (2021) Acute simple cystitis in men. In: A. Bloom (Ed.), *UpToDate*. Retrieved March 1, 2022, from <https://www.uptodate.com/contents/acute-simple-cystitis-in-men>
- Nicolle, L. E., Bradley, S., Colgan, R., Rice, J. C., Schaeffer, A., & Hooton, T. M. (2005) Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*, 40(5), 643-654. <https://doi.org/10.1086/427507>
- Nicolle, L. E., Gupta, K., Bradley, S. F., Colgan, R., DeMuri, G. P., Drekonja, D., Eckert, L. O., Gerrlings, S. E., Koves, B., Hooton, T. M., Juthani-Mehta, M., Knight, S. L., Saint, S., Schaeffer, A. J., Trautner, B., Wullt, B., & Siemieniuk, R. (2019) Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 68(10), e83-e110. <https://doi.org/10.1093/cid/ciy1121>
- Perry, A., & Potter, P. (2010) *Clinical nursing skills and techniques* (7th ed.). Mosby.

E. Recommended Procedure for Using Urinary Catheter (Indwelling Foley) for Collecting Urine for Culture

NOTE: Institutions may wish to adopt the following as a local procedure.

PRINCIPLES:

- **Procedure:** Collection of urine for culture from a patient with a urinary catheter optimally should be performed by using the catheter sampling port. Suboptimal collection and/or transport of urine can lead to a false-positive urine culture, resulting in a misdiagnosis of urinary tract infection and unnecessary treatment with antibiotics.
- **Timing:** Urine samples should be plated within 2 hours of collection unless specimens are refrigerated immediately (and plated within 24 hours) or kept in a preservative tube (and plated within 48 hours).
- **14-Day Indication:** Patients with a suspected UTI and a Foley urinary catheter in place for 14 days or longer should have the Foley catheter replaced prior to collecting urine for culture and antimicrobial treatment. (This does not apply to supra-pubic catheters.)
Note: The 14-day indication for a Foley catheter change prior to obtaining urine culture is indicated in the National Healthcare Safety Network (NHSN) long term care UTI protocol and has been noted by Clinical Infectious Disease research (see Hooton, T., 2010 in [References](#)) to hasten resolution of symptoms and to reduce the risk of subsequent CA bacteriuria.
➔ See <http://www.cdc.gov/nhsn/PDFs/LTC/LTCF-UTI-protocol-current.pdf>.

PROCEDURAL GUIDELINES:

1. **Equipment:**

- a. Alcohol or chlorhexidine (CHG) wipes
- b. Specimen C&S tube with preservative, specimen UA tube
- c. Sterile Luer-Lok™ access device package
- d. Biohazard bag, patient label, and lab slip
- e. Sharps container
- f. PPE, as appropriate (gloves, eye protection)

2. **Planning and Preparation:**

- a. Obtain order to change the urinary catheter from the provider if the catheter has been in 14 days or longer, or if it is unknown how long the catheter has been in.
- b. Change the urinary catheter per facility protocol or policy.
- c. Use Standard Precautions (see Infection Control manual).
- d. Explain the procedure to the patient.
- e. Check that the indwelling sample port will accept the Luer-Lok access device. (The Bard E-Z Lock Sampling Port accepts a Luer-Lok or slip tip syringe).
- f. Identify how the sample will get to lab to be plated in the appropriate amount of time.

3. **Collection Procedure:**

Preparation:

- a. Identify the patient using two identifiers.
- b. Wash hands.
- c. Apply gloves and other PPE, as needed.
- d. Kink drainage tubing (approximately 12 inches) below the sampling port until urine is visible under the access site.
★ *Urine is NEVER collected for culture from urinary drainage bags.*
- e. Cleanse sampling port with alcohol or CHG; scrub for 15–20 seconds.
- f. Using aseptic technique, position the Luer-Lok access device over the center of the sampling port. Push it in, and rotate the access device clockwise onto the sampling port until it fits securely.

Urine Collection:

- g. Center the C&S tube over the holder portion of the access device and push it in. Once the tube is adequately filled, remove the tube from the holder.
- h. Check that tube is filled to at least the minimum fill line (4ml of urine).
- i. Invert the tube 8–10 times.
- j. Repeat steps g–i with UA tube, if ordered.
- k. Remove access device by rotating it counterclockwise.
- l. Unclamp the drainage tube.
- m. Discard the Luer-Lok device immediately into sharps container.

(continues on next page)

Process Specimen:

- n. Label collection container(s) in front of patient with:
 - 1) Date/time of collection.
 - 2) Method of collection (and type of catheter).
 - 3) Note if patient is on antibiotic therapy.
- o. Place specimen(s) in biohazard bag(s)
- p. Remove gloves and wash hands.
- q. Send specimen to lab—ideally within 15 minutes of collecting, but no later than 48 hours if in a preservative C&S tube; or no later than 24 hours if not in preservative, but immediately refrigerated ; or within 2 hours post-collection if not refrigerated and not in preservative.

4. Documentation:

In the Bureau Electronic Medical Record (BEMR), NMOS, or clinical encounter (depending on institution policy):

- a. Record the reason for specimen collection.
- b. Document whether collected via Foley or suprapubic catheter.
- c. Document if catheter was changed immediately prior to collection of specimen.
- d. Note the appearance, odor, color, or any unusual characteristics of the urine.

SOURCES FOR SECTION E:

- Eisinger, S. W., Schwartz, M., Dam, L., & Riedel, S. (2013) Evaluation of the BD Vacutainer Plus Urine C&S Preservative Tubes compared with non-preservative urine samples stored at 4° C and room temperature. *Am J Clin Pathol*, 140(3), 306-313.
<https://doi.org/10.1309/AJCP5ON9JHXVNQOD>
- Gould, C. V., Umscheid, C. A., Agarwal, R. K., Kuntz, G., Pegues, A. A., & the Healthcare Infection Control Practices Advisory Committee (HICPAC). (2019) *Guideline for prevention of catheter-associated urinary tract infections 2009*
<https://www.cdc.gov/infectioncontrol/pdf/guidelines/cauti-guidelines-H.pdf>
- Clinical and Laboratory Standards Institute. (2009) *Urinalysis; Approved Guideline – Third Edition*. CLSI document GP16-A3.

12. ASYMPTOMATIC BACTERIURIA

CONTENTS

A. Key Points	
B. Differentiating Urinary Tract Infection from Asymptomatic Bacteriuria.....	
C. Screening Recommendations	
D. References	

A. Key Points

- Asymptomatic bacteriuria (ASB) is a common finding in some healthy females, as well as in males and females with genitourinary tract abnormalities.
- An asymptomatic patient with a positive urinary culture has either ASB or a contaminated urine specimen.
- Cultured urine often grows organisms in the absence of infection, since the urine passes through tissue that is typically colonized with bacteria.
- **ASB should not be routinely treated with antibiotics, with two exceptions:**
 - Pregnant patients
 - Patients scheduled for genitourinary surgical procedures

B. Differentiating UTI from ASB

- Urine culture must always be interpreted in the context of a urinalysis and patient symptoms.
- The presence of dysuria symptoms is the main distinguisher between ASB and UTI.
 - Defined as urgency, frequency, or suprapubic pain.
 - Dark, smelly urine indicates dehydration, not infection. Patients should be encouraged to increase fluid intake
- Both UTI and ASB patients will have bacteria in the urine in concentrations of >100,000 CFU/ml.
- ASB may present +/- pyuria (WBC in urine). Pyuria accompanying bacteriuria is very common and is not an indication for antibiotic therapy.

C. Screening Recommendations

PATIENT POPULATIONS THAT SHOULD NOT BE SCREENED/TREATED FOR ASB

- Healthy, nonpregnant pre-menopausal women AND healthy, post-menopausal women
- Older, community-dwelling OR residents in LTC facilities, including functionally/cognitively impaired
- Diabetics
- Renal transplant patient who underwent transplant >1 month prior
- Solid organ transplant other than kidney transplant
- Patients with spinal cord injury
- Short-term (<30 day) indwelling urethral catheter (indwelling suprapubic catheters likely similarly)
- Long-term indwelling catheters
- Elective *non*-urologic surgery patients
- Implanted urologic devices

PATIENT POPULATIONS THAT SHOULD BE SCREENED/TREATED FOR ASB

- **Pregnant women:**
 - Urine culture should be collected at 1 of the initial visits early in pregnancy
 - If ASB is detected, 4-7 days of antimicrobial treatment is recommended (dependent on antibiotic chosen)
 - Nitrofurantoin and β -lactam antibiotics are preferred in pregnancy due to their established safety, however these regimens are less effective as short-course therapy.
 - Empiric therapy is not generally recommended or appropriate, C&S should provide the necessary information for tailored therapy.
- **Endoscopic urologic procedures associated with mucosal trauma** (obtain C&S and treat prior to procedure):
 - Urine C&S should be performed *prior* to procedure and targeted antimicrobial therapy should be targeted based on C&S. Empiric therapy is not recommended.
 - A short course of 1-2 doses is recommended starting 30-60 minutes before the procedure.

D. References

- Nicolle, L. E., Bradley, S., Colgan, R., Rice, J. C., Schaeffer, A., & Hooton, T. M. (2005) Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*, 40(5), 643-654. <https://doi.org/10.1086/427507>
- Nicolle, L. E., Gupta, K., Bradley, S. F., Colgan, R., DeMuri, G. P., Drekonja, D., Eckert, L. O., Gerrlings, S. E., Koves, B., Hooton, T. M., Juthani-Mehta, M., Knight, S. L., Saint, S., Schaeffer, A. J., Trautner, B., Wullt, B., & Siemieniuk, R. (2019) Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 68(10), e83-e110. <https://doi.org/10.1093/cid/ciy1121>

13. *HELICOBACTER PYLORI*

CONTENTS

A. Key Points	1
B. Treatment	2
C. References	3

A. Key Points

- *Helicobacter pylori* (*H. pylori*) is a gram-negative bacteria commonly found in the gastrointestinal (GI) tract affecting about one-half of the world's population. The majority of people infected with *H. pylori* have no symptoms. However, it has been associated with many conditions, including peptic ulcer disease (PUD), gastritis, and much less commonly, malignancy.
- Testing and treating for *H. pylori* is indicated for the following:
 - All patients with active PUD or a history of PUD, for whom eradication therapy has not already been prescribed.
 - Patients age less than 55 years of age who have un-investigated dyspepsia, and low suspicion for malignancy
- Testing and treating for *H. pylori* may also be helpful in patients taking chronic NSAID therapy.
- Testing and treating may also be indicated under certain other circumstances on a case-by-case basis. A list of specific such scenarios is outside the scope of this guidance.
- Diagnosis can be made with a variety of testing methods (e.g., urea breath test, stool testing, antibody testing, and tissue sampling). If a patient is tested and found to have *H. pylori*, treatment should be given.
- First-line treatment should be guided by the presence of risk factors for macrolide resistance and the presence of penicillin allergy. Risk factors for macrolide resistance include:
 - Prior exposure to macrolide therapy for any reason
 - High local clarithromycin resistance rates >15% or eradication rates with clarithromycin triple therapy ≤85%
 - ★ If this information is not available locally, it is generally assumed that clarithromycin resistance rates are >15%.
- At least 4 weeks after completion of treatment and after PPI therapy has been withheld for 1-2 weeks, re-testing should be performed to verify eradication.

B. Treatment

FIRST-LINE TREATMENT OPTIONS:

- **BISMUTH QUADRUPLE THERAPY (IF RISK FOR MACROLIDE RESISTANCE):**
Duration of treatment is 14 days:
 - Omeprazole 20 mg po bid
 - Bismuth subsalicylate 524 mg po qid
 - Metronidazole 500 mg po qid
 - Tetracycline 500 mg po qid (**do not substitute doxycycline)
- **NON-BISMUTH QUADRUPLE THERAPY:**
Duration of treatment is 14 days:
 - Omeprazole 20mg po bid
 - Amoxicillin 1000mg po bid
 - Clarithromycin 500mg po bid (**do not substitute azithromycin)
 - Metronidazole 500mg po bid

ALTERNATIVE TREATMENT OPTIONS (FOR THOSE THAT FAIL ABOVE REGIMENS):

- **LEVOFLOXACIN TRIPLE THERAPY**
Duration of treatment is 14 days:
 - Levofloxacin 500 mg po qd
 - Omeprazole 20 mg po bid
 - Amoxicillin 1000 mg po bid
- **BISMUTH QUADRUPLE THERAPY (SAME AS ABOVE)**

ANTIBIOTIC RESISTANCE

- Antimicrobial resistance in *H. pylori* is well-documented in the literature, particularly to metronidazole and clarithromycin, and rates do appear to be rising. Response rates with first-line regimens range from 70-85% with response falling due to increasing resistance.
- Options **NOT** recommended as first line therapy due to resistance include:
- Sequential non-bismuth quadruple therapy
- Triple therapy: PPI + amoxicillin + either metronidazole or clarithromycin
- The use of amoxicillin and tetracycline historically has been minimally affected by resistance.
- When re-treating, the selected antibiotics should be different from the antibiotics used during the initial regimen.

C. References

- Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017) ACG Clinical guideline: Treatment of Helicobacter pylori infection. *Am J Gastroenterol*, 112(2), 212-239. [doi: 10.1038/ajg.2016.563](https://doi.org/10.1038/ajg.2016.563)
- Kim, K. (2021). Gastric/Duodenal Ulcer, Helicobacter pylori. *Sanford Guide*. Retrieved March 1, 2022 from <https://webedition.sanfordguide.com/en/sanford-guide-online/disease-clinical-condition/duodenal-ulcer-gastric-ulcer>
- Thomas Lamont, J. (2021) Treatment regimens for Helicobacter pylori in adults. In S. Grover (Ed.), *UpToDate*. Retrieved March 1, 2022 from <https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori-in-adults>

14. DENTAL INFECTION

CONTENTS

A. Key Points	1
B. Treatment	1
C. Algorithm: Treatment of Immunocompetent Patients with Pulpal and/or Periapical Condition in which DCDT is Immediately Available	3
D. Algorithm: Treatment of Immunocompetent Patients with Pulpal and/or Periapical Condition in which DCDT is Immediately Available	4
E. Prophylaxis	5
F. References.....	6

A. Key Points

- Dental infection primarily involves pulpal and periodontal infections. Secondary infections—including those involving soft tissues, as well as sinus infections—pose special treatment challenges.
- The American Dental Association (ADA) provides clinical recommendations for the urgent management of dental infections using antibiotics as adjuncts to definitive conservative dental treatment (DCDT) in immunocompetent adults.
- ADA suggests the use of antibiotics for target conditions only when systemic involvement is present, and immediate DCDT should be prioritized in ALL cases.
 - ★ *Antibiotic usage should not be a substitute for interventional procedures.*
- Although the expert panel recommends both amoxicillin and penicillin as first-line treatments, amoxicillin is preferred over penicillin because it is more effective against various gram-negative anaerobes and its lower incidence of gastrointestinal side effects.
- As an alternative for patients with a history of penicillin allergy, but without a history of anaphylaxis, angioedema, or hive reaction to penicillin, ampicillin, or amoxicillin, the panel suggests dentists prescribe oral cephalexin.
 - ★ *The anaerobic activity of cephalexin is not well described for some oral pathogens. Clinicians should have a low threshold to add metronidazole to cephalexin therapy in patients with a delayed response to antibiotics.*
- As an alternative for patients with a history of a penicillin allergy of anaphylaxis, angioedema, or hives with penicillin, ampicillin, or amoxicillin, the panel suggests dentists prescribe oral azithromycin or oral clindamycin.
- Clinicians should reevaluate the patient within 3 days of prescribing antibiotic therapy. Dentists should instruct the patient to discontinue antibiotics 24 hours after patient’s symptoms resolve, irrespective of reevaluation after 3 days.
- Third generation cephalosporin antibiotics such as ceftriaxone are generally inappropriate for dental indications
 - ★ *In the BOP, dental use of ceftriaxone requires Regional Chief Dentist approval.*

B. Treatment


For urgent situations in dental settings in which pulpotomy, pulpectomy, nonsurgical root canal, or incisions for drainage of abscess ARE NOT an immediate option (cannot be completed during the same visit as the assessment):

- ★ If the clinical condition worsens or if there is concern for deeper space infection or immediate threat to life, refer patient for urgent evaluation.
 - For immunocompetent adults with symptomatic irreversible pulpitis with or without symptomatic apical periodontitis
 - Oral systemic antibiotics *are not recommended*.
 - Clinicians should refer patients for DCDT while providing interim monitoring.
 - For immunocompetent adults with pulp necrosis and acute apical abscess with systemic involvement
 - Oral amoxicillin (500 mg, 3 times per day, 3-7 days) or oral penicillin V potassium (500 mg, 4 times per day, 3-7 days)
 - Clinicians should also not delay referral for DCDT.
 - For immunocompetent adults with pulp necrosis and symptomatic apical periodontitis
 - Oral systemic antibiotics *are not recommended*.
 - Clinicians should refer patients for DCDT while providing interim monitoring.
 - If DCDT is not feasible, a prescription for oral amoxicillin (500 mg, 3 times per day, for 3-7 days) or oral penicillin V potassium (500 mg, 4 times per day, 3-7 days) should be provided.
 - For immunocompetent adults with pulp necrosis and localized acute apical abscess
 - Oral amoxicillin (500 mg, 3 times per day, 3-7 days) or oral penicillin V potassium (500 mg, 4 times per day, 3-7 days).
 - Clinicians also should provide urgent referral as DCDT should not be delayed.


For urgent situations in dental settings and pulpotomy, pulpectomy, nonsurgical root canal, or incision for drainage of abscess ARE an immediate option (can be completed during the same visit as the assessment):

- For immunocompetent adults with pulp necrosis and symptomatic apical periodontitis or localized acute apical abscess
 - Oral systemic antibiotics are not recommended.
 - Clinicians should refer patients for DCDT while providing interim monitoring.
- For immunocompetent adults with symptomatic irreversible pulpitis with or without symptomatic apical periodontitis
 - Oral systemic antibiotics are not recommended.
 - Clinicians should refer patients for DCDT while providing interim monitoring.
- For immunocompetent adults with pulp necrosis and acute apical abscess with systemic involvement
 - Urgent DCDT in conjunction with prescribing oral amoxicillin (500 mg tid x 3-7 days) or oral penicillin V potassium (500 mg qid x 3-7 days)

C. Algorithm: Treatment of Immunocompetent Patients with Pulpal and/or Periapical Condition in which DCDT is Immediately Available



D. Algorithm: Treatment for Immunocompetent Patients with Pulpal and/or Periapical Condition in which DCDT is Not Immediately Available



E. Prophylaxis

- When indicated, antibiotic prophylaxis should cover viridans group streptococci and be given 30–60 minutes prior to all dental procedures involving manipulation of gingival tissue or the periapical region of teeth, or perforation of the oral mucosa.
- Prophylaxis is indicated to help prevent infective endocarditis (IE) in select patient populations. The American Dental Association (ADA) and the American Heart Association (AHA) recommend the use of prophylaxis to prevent IE in the following cardiac conditions:
 - **NON-CONGENITAL:** Prosthetic cardiac valve, prosthetic material used in a cardiac valve repair, history of IE, cardiac transplant that develops cardiac valvulopathy.
 - **CONGENITAL:** Unrepaired or incompletely repaired cyanotic congenital heart disease; during the first six months after a procedure to completely repair a congenital heart defect with prosthetic material or device; and repaired congenital heart defect with residual defect at the site or adjacent to the site, or a prosthetic patch or device.
- Prophylaxis for those with prosthetic joint replacements is controversial due to lack of evidence. A 2014 ADA expert panel stated, in general, evidence DOES NOT support the use of prophylactic antibiotics prior to dental procedures to prevent prosthetic joint infections.

★ *Clindamycin is no longer recommended for antibiotic prophylaxis for a dental procedure.*

Dental Prophylaxis for Bacterial Endocarditis Prevention in Adult Patients

SCENARIO	ROUTE	PROPHYLACTIC REGIMEN (Administer ONE of the following medications 30–60 minutes before the procedure.)	
NOT ALLERGIC to Penicillins or Ampicillin	Oral	Amoxicillin	2 grams
	IM ¹	Ampicillin	2 grams
ALLERGIC to Penicillins or Ampicillin	Oral	Cephalexin ²	2 grams
		Doxycycline	100 milligrams
		Azithromycin or clarithromycin	500 milligrams
	IM ¹	Cefazolin or ceftriaxone ^{2,3}	1 gram

¹ IM = Intramuscular (use if patient is unable to take oral medication).

² Cephalosporins should NOT be used in persons with a history of anaphylaxis, angioedema, or urticaria from use of penicillins or ampicillin.

³ Broad spectrum antibiotics such as ceftriaxone are generally inappropriate for dental indications. In the BOP, dental use of ceftriaxone requires Regional Chief Dentist approval.

Adapted from:

Table 5 in Wilson, et al. *Prevention of Infective Endocarditis: Guidelines from the American Heart Association*. See [References](#) on next page.

F. References

- Sollecito, T.P., Abt, E., Lockhart, P.B., Truelove, E., Paumier, T. M., Tracy, S. L., Tampi, M., Beltran-Aguilar, E. D., & Frantsve-Hawly, J. (2015) The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: evidence-based clinical practice guideline for dental practitioners—a report of the American Dental Association Council on Scientific Affairs. *JADA*, 146(1), 11-16. <https://doi.org/10.1016/j.adaj.2014.11.012>
- Wynn, R.L. (2015) *Drug information handbook for dentistry* (21st ed.) (T. F. Meiller & H. L. Crossley, Eds). Lexicomp.
- Wilson, W., Taubert, K. A., Gewitz, M., Lockhart, P. B., Baddour, L. M., Levison, M., Bolger, A., Cabell, C. H., Takahashi, M., Baltimore, R. S., Newburger, J. W., Strom, B. L., Tani, L. Y., Gerber, M., Bonow, R. O, Pallasch, T., Shulman, S. T., Rowley, A. H., Burns, J. C., ... Durack, D. T. (2008) Prevention of infective endocarditis: guidelines from the American Heart Association. *JADA*, 139(sup.1), S11-S24. 2008;139:3s–24s. <https://doi.org/10.14219/jada.archive.2008.0346>
- Lockhart, P. B., Tampi, M. P., Abt, E., Aminoshariae, A., Durking, M. J., Fouad, A. F., Gopal, P., Hatten, B. W., Kennedy, E., Lang, M. S., Patton, L. L., Paumier, T., Suda, K. J., Pilcher, L., Urquhart, O., O'Brien, K. K., & Carrasco-Labra, A. (2019) Evidence-based clinical guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling. *JADA*, 150(11), 906-921. <https://doi.org/10.1016/j.adaj.2019.08.020>
- Wilson, W. R., Gewitz, M., Lockhart, P. B., Bolger, A. F., DeSimone, D. C., Kazi, D. S., Couper, D. J., Beaton, A., Kilmartin, C., Miro, J. M., Sable, C., Jackson, M. A., & Baddour, L. M. (2021) Prevention of Viridans group streptococcal infective endocarditis: A scientific statement from the American Heart Association. *Circulation*, 143(20), e963-e978. <https://doi.org/10.1161/CIR.0000000000000969>

15. SURGICAL SITE INFECTION PROPHYLAXIS

CONTENTS

A. Key Points	1
B. Common Surgical Pathogens	1
C. References	1

A. Key Points

- The majority of surgical procedures for BOP inmates occur at outside hospital facilities, and prophylactic regimens and routines of the outside facility should be followed to prevent infections. Recommendations that do not follow current, evidence-based practices should be discussed with an Antimicrobial Stewardship Pharmacist and/or your Regional Medical Director.
- *Staphylococcus aureus* is the most common pathogen causing surgical site infection (SSI). The universal use of intranasal mupirocin is discouraged; however, pre-operative use in specific settings (e.g., gastrointestinal, orthopedic procedures) may be indicated. The data are most compelling in cardiac and orthopedic surgery patients.
- Pre-operative use of agents such as chlorhexidine should be used in accordance with outside hospital recommendation through a non-formulary submission.
- Cefazolin is, for the majority of surgical procedures, the drug of choice. If patient is unable to tolerate a cephalosporin, vancomycin or clindamycin IV are secondary options.

B. Common Surgical Pathogens

- *Skin and soft tissue infections (SSTIs)* after clean procedures are predominantly caused by normal skin flora:
 - *Staphylococcus aureus*
 - Coagulase-negative staphylococci
- The predominant organism after clean-contaminated procedures (abdominal procedures; heart, kidney, and liver transplants) are gram-negative rods and enterococci, in addition to skin flora.

C. References

- Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Per, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., Steinberg, J. P., & Weinstein, R. A. (2013) Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm*, 70(3), 195-283. <https://doi.org/10.2146/ajhp120568>

16. EPIDIDYMITIS

CONTENTS

A. Key Points	1
B. Treatment	1
C. References	2

A. Key Points

- Clinical features of acute epididymitis include localized testicular pain with tenderness and swelling on palpation of the affected epididymis.
- Diagnosis is made presumptively based on history and physical examination. Other causes requiring urgent surgical intervention, such as testicular torsion, must be ruled out.
- In all suspected cases, a urinalysis, urine culture, and a urine nucleic acid amplification test (NAAT) for *N. gonorrhoeae* and *C. trachomatis* should be performed
 - Urinalysis and urine culture are often negative in patients without lower urinary tract symptoms
 - *N. gonorrhoeae* and *C. trachomatis* are the most common organisms responsible for acute epididymitis in men under age 35

B. Treatment

- Empiric treatment should be started pending results of NAAT and culture results
 - **Patients age < 35 or at risk of sexually transmitted infections**
 - Ceftriaxone 500 mg IM one-time dose + Doxycycline 100 mg po BID x 10 days
 - Cephalosporin allergy – Gentamicin 240 mg IM one-time dose + Azithromycin 2,000 mg po one-time dose
 - ★ *Fluoroquinolones are not recommended if gonorrhea is suspected due to widespread resistance*
 - **Patients age ≥35 who are at low risk of sexually transmitted infections**
 - Levofloxacin 500-750 mg po QD x 10 days
 - **Patients of any age who practice insertive anal intercourse**
 - Ceftriaxone 500 mg IM one-time dose + Levofloxacin 500 mg po QD x 10 days

- Alternative treatment for those unable to tolerate primary regimens
 - Patients age <35
 - Levofloxacin 500 mg po qd x 10 days
 - Patients age ≥35
 - Ampicillin-sulbactam 3 grams IV q6h **OR**
 - Amoxicillin-clavulanate 875/125 mg po BID **OR**
 - Ceftriaxone 2 grams IV q24h **OR**
 - Piperacillin-tazobactam 4.5 grams IV q6h **OR**
 - Trimethoprim-sulfamethoxazole DS 800-160 mg po BID x 10-14 days if sexually transmitted infection is unlikely and local resistance is <20% for *E. coli*

C. References

- Eyre, R. C. (2022) Acute scrotal pain in adults. In J. Givens (Ed.), *UpToDate*. Retrieved March 30, 2022 from <https://www.uptodate.com/contents/acute-scrotal-pain-in-adults>
- Kim, K. (2021) Epididymo-orchitis. *Sanford Guide*. Retrieved March 1, 2022 from <https://webedition.sanfordguide.com/en/sanford-guide-online/disease-clinical-condition/epididymo-orchitis>
- Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) Sexually transmitted infections treatment guidelines, 2021. *MMWR Recomm Rep* 2021, 70(4), 1-187. <http://dx.doi.org/10.15585/mmwr.rr7004a1>

APPENDIX A: INTERPRETATION OF A CULTURE AND SENSITIVITY REPORT “C & S”

Key points

- Culture and Sensitivity testing is used to determine the likelihood that a particular antibiotic will be effective in stopping the growth of the bacterial microorganism causing the infection.
- Oftentimes, when a culture of a potentially infected site is ordered, the sensitivity testing is simultaneously ordered. However, sensitivity testing is usually only performed when the culture recovers pathogenic bacteria. The number of viable bacterial cells is defined as a colony forming unit (CFU).
- Typically, a CFU/ml \geq 100,000 is indicative of bacterial infection, in conjugation with symptoms.
 - NOTE: Asymptomatic bacteriuria often reports CFU/ml \geq 100,000, however without patient symptoms, antibiotic therapy should not be started (exceptions apply).
- There are some organisms that are usually sensitive to antibiotics and typically not analyzed by lab. For example:
 - *Streptococci* will always be sensitive to penicillin
 - *Stenotrophomonas* would only be sensitive to trimethoprim/sulfamethoxazole or levofloxacin

What the C & S report tells you	What the C & S report does <u>NOT</u> tell you
The pathogen present (i.e. <i>Escherichia coli</i>)	Does NOT identify infection vs. colonization vs. contamination
Sensitivity results based on pre-specified lab criteria	Does NOT tell you which antibiotic choice is best for the type of infection

C&S Definitions

- **MIC (minimum inhibitory concentration):** The results of susceptibility testing are based on MIC, which is the lowest concentration of each antibacterial agent needed to inhibit growth of an organism.
 - ★ *MIC values differ between bacteria. MIC values between drugs CANNOT be compared.*
- **Breakpoint:** A discriminatory concentration of an antibiotic which defines isolates as susceptible, intermediate, or resistant to the antibiotic (standards published by FDA, CLSI, & EUCAST)
 - **Susceptible** – The isolate is likely to respond to treatment with this drug at the recommended dosage for the infection type. Clinical efficacy is expected.
 - **Intermediate** – The isolate may be “moderately susceptible” to the antimicrobial agent at a higher or more frequent dosage. In addition, it may be effective only in specific body sites where the antibiotic penetrates to provide adequate concentrations.
 - **Resistant** – The antimicrobial agent will not be effective at inhibiting the growth of the organism at the usual achievable concentrations of the agent with normal dosage schedules.

Important considerations when choosing an antibiotic

- Choose the narrowest spectrum agent within the scope of infection
- Identify the most likely pathogen for the infection
- Start with a beta-lactam if possible (especially in severe infections)
 - Exceptions apply (e.g. atypical infections)
- Do **NOT** compare MICs between drugs
 - Each antibiotic has different serum and tissue concentrations
 - Never use the smallest number just because it is the smallest number
- Microbiology can perform additional tests if needed (i.e. fosfomycin rarely reported but can be tested)
- Correlate gram stain findings with culture results. On a given sample try to use the gram stain to determine infection depending on the amount of white cells on that particular gram stain.
- Just because a drug is “susceptible”, does not mean it will always be effective for the intended infection. The following should also be considered:
 - Type of infections (complicated vs uncomplicated, IV or PO needed etc.)
 - Site of action
 - Pharmacodynamic parameters
 - Tissue penetration
 - Inducible resistance
 - Beta-lactamase testing
 - Patient specific parameters (male vs female, age, drug interactions etc.)

REMEMBER: A culture and susceptibility report identifies bacteria present; however, **it does not differentiate between infection, colonization, or contamination.** Susceptibility results are based on *in vitro* studies which do not necessarily reflect or predict *in vivo* efficacy. The report does not select the antibiotic to be used. Providers should always **TREAT THE PATIENT** and **NOT THE LAB.**

Sample C & S report

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
Urine Culture, Routine						
Urine Culture, Routine						
Final report		Abnormal				01
Result 1						
Escherichia coli		Abnormal				01
Greater than 100,000 colony forming units per mL						
Cefazolin <=4 ug/mL						
Cefazolin with an MIC <=16 predicts susceptibility to the oral agents cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, cephalixin, and loracarbef when used for therapy of uncomplicated urinary tract infections due to E. coli, Klebsiella pneumoniae, and Proteus mirabilis.						
Antimicrobial Susceptibility						01
** S = Susceptible; I = Intermediate; R = Resistant **						
P = Positive; N = Negative						
MICs are expressed in micrograms per mL						
Antibiotic	RSLT#1	RSLT#2	RSLT#3	RSLT#4		
Amoxicillin/Clavulanic Acid	S					
Ampicillin	S					
Cefepime	S					
Ceftriaxone	S					
Cefuroxime	S					
Ciprofloxacin	S					
Ertapenem	S					
Gentamicin	S					
Imipenem	S					
Levofloxacin	S					
Meropenem	S					
Nitrofurantoin	S					
Piperacillin/Tazobactam	S					
Tetracycline	S					
Tobramycin	S					
Trimethoprim/Sulfa	S					

References

Antibiotic Susceptibility Testing. June 2019. <https://labtestsonline.org/tests/antibiotic-susceptibility-testing>

Interpretation of a Culture and Sensitivity Report.

<https://med.unr.edu/statewide/echo/clinics/antibiotic-stewardship>

Minimum Inhibitory Concentration Assay. Case Studies in Microscopy.

<https://courses.cit.cornell.edu/biomi290/microscopycases/methods/MIC.Method.htm>

Sensitivity Analysis. www.healthline.com/health/sensitivity-analysis

The United States Committee on Antimicrobial Susceptibility Testing (USCAST). Breakpoint tables for interpretation of MIC and zone diameter results. Version 5.3, 2019. <http://www.uscast.org>